https://trial.medpath.com/news/55171d2f674aad6f/calcium-carbonate-supplementation-for-the-prevention-of-preeclampsia-in-high-risk-pregnant-women 2024-10-03T15:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/1c01825291ef380b/convalescent-plasma-might-have-saved-thousands-more-lives-during-covid-pandemic 2024-10-03T15:32:40+00:00 weekly 0.7 https://trial.medpath.com/news/608f3815572024ea/stem-cell-therapy-might-repair-vision-robbing-holes-in-retinas 2024-10-03T15:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/b96f4b127fa82640/investigating-early-diagnosis-through-genomic-medicine-nhs-england 2024-10-03T15:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/a118f43b9af82c38/bayer-s-kerendia-demonstrates-success-in-phase-3-clinical-trials-for-treatment-of-heart-failure 2024-10-03T14:36:40+00:00 weekly 0.7 https://trial.medpath.com/news/44710f0510cb7b42/tirzepatide-semaglutide-more-efficacious-than-other-fda-approved-drugs-for-weight-loss 2024-10-03T14:24:51+00:00 weekly 0.7 https://trial.medpath.com/news/7d6914b6085078ca/peph-newsletter-october-2024-national-institute-of-environmental-health-sciences 2024-10-03T14:17:43+00:00 weekly 0.7 https://trial.medpath.com/news/784008c58ef1ff0c/first-line-versamune-hpv-vaccine-bolsters-responses-with-soc-pembrolizumab-in-onclive 2024-10-03T14:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/3bd4ad7dd001a5c2/genomic-testing-saved-my-life-illumina 2024-10-03T13:53:02+00:00 weekly 0.7 https://trial.medpath.com/news/0d26d895d6b08bbc/mangorx-introduces-oral-tirzepatide-glp-1-receptor-agonist-for-advanced-weight-loss-solutions 2024-10-03T12:41:14+00:00 weekly 0.7 https://trial.medpath.com/news/e38b4f0b2778290a/elucid-scoops-fda-approval-for-ai-cardiovascular-risk-diagnostic-yahoo-finance 2024-10-03T12:32:56+00:00 weekly 0.7 https://trial.medpath.com/news/72f15c481beca5b8/resolution-therapeutics-announces-ps63-5-million-series-b-financing-and-chair-appointment 2024-10-03T12:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/faa205142a2204b4/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of 2024-10-03T12:15:48+00:00 weekly 0.7 https://trial.medpath.com/news/18ecd8e2dbfb2295/immutep-completes-patient-enrolment-in-randomised-phase-ii-of-aipac-003-trial-in 2024-10-03T12:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/5355edf5e18bf303/major-alzheimer-s-breakthrough-as-experts-discover-double-whammy-drug-that-destroys 2024-10-03T12:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/31f729a6daa69046/alembic-pharma-jumps-4-on-us-fda-approves-anti-seizure-drug-worth-163-million 2024-10-03T12:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/f54cd97686a9d864/new-jersey-biotech-reports-positive-survival-data-the-streetwise-reports 2024-10-03T11:17:40+00:00 weekly 0.7 https://trial.medpath.com/news/ba789a41992ab83a/avidity-biosciences-announces-fda-removed-partial-clinical-hold-on-delpacibart 2024-10-03T11:15:40+00:00 weekly 0.7 https://trial.medpath.com/news/5f7a7cd5a7f7fae6/validation-of-a-digital-pathology-based-mmai-model-in-oligometastatic-castration-sensitive 2024-10-03T11:09:47+00:00 weekly 0.7 https://trial.medpath.com/news/1f0536fd141785a4/first-patient-dosed-in-phase-ii-ca-nine-trial-of-tlx250-cdx-for-detection-of-recurrent 2024-10-03T11:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/e50efe43af0417ae/eye-on-pharma-high-strength-trastuzumab-biosimilar-originator-coverage-removals 2024-10-03T11:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/9846f6ef0dc7d9c5/rwanda-to-kick-off-vaccine-and-therapeutic-clinical-trials-for-marbug-disease-in-several-weeks 2024-10-03T11:02:44+00:00 weekly 0.7 https://trial.medpath.com/news/4d21e74c11f3d7d5/novavax-nvax-stock-rises-19-after-fda-approval-for-updated-covid-19-vaccine 2024-10-03T10:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/22119daa305037e0/could-lithium-supplements-ease-the-brain-fog-of-long-covid 2024-10-03T10:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/b0b8e6c8ba3ed09c/fda-approved-zunveyl-for-alzheimer-s-symptoms-on-the-way-in-2025-being-patient 2024-10-03T10:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/62ff3cf9d67d124a/datacc-by-dime-awarded-fda-grant-to-boost-use-of-sensor-based-digital-health 2024-10-03T09:51:02+00:00 weekly 0.7 https://trial.medpath.com/news/ba54a305d5b37991/eli-lilly-to-invest-4-5bn-for-drug-manufacturing-and-trial-medicine-production 2024-10-03T09:25:28+00:00 weekly 0.7 https://trial.medpath.com/news/415a6ffd05cbd7ae/october-3-2024-jama-commentary-highlights-gap-between-research-results-and 2024-10-03T08:01:18+00:00 weekly 0.7 https://trial.medpath.com/news/7e6dacab412b45ac/phase-iii-randomized-clinical-trial-of-efficacy-and-safety-of-amlodipine-and-candesartan 2024-10-03T07:50:30+00:00 weekly 0.7 https://trial.medpath.com/news/a9e46a4ae83bc9d0/bpd-maintains-qol-vs-pvd-supporting-its-use-as-a-new-soc-in-r-r-myeloma-onclive 2024-10-03T07:42:17+00:00 weekly 0.7 https://trial.medpath.com/news/3a167c0930aeb0be/korean-clinical-trials-prove-exosomes-peptides-and-spicules-outperforms-retinol-in-anti-ageing 2024-10-03T07:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/92ece6b4ed53dbba/new-research-targets-cognitive-recovery-after-brain-injury-rowan-today 2024-10-03T07:33:37+00:00 weekly 0.7 https://trial.medpath.com/news/454e2c86d5f87707/revvity-s-euroimmun-launches-solution-for-specific-typing-of-alzheimer-s-disease-news-medical 2024-10-03T07:26:04+00:00 weekly 0.7 https://trial.medpath.com/news/b4bddb41b0bf9132/radiopharm-closes-in-on-cancer-fighting-drug-approval-the-west-australian 2024-10-03T07:13:32+00:00 weekly 0.7 https://trial.medpath.com/news/2413a728a988caf7/mrd-negativity-is-sustained-after-cessation-of-lenalidomide-maintenance-in-multiple-myeloma 2024-10-03T07:09:10+00:00 weekly 0.7 https://trial.medpath.com/news/32018579c8cea67e/camber-pharmaceuticals-achieves-full-dscsa-compliance-ahead-of-2024-deadline 2024-10-03T07:06:40+00:00 weekly 0.7 https://trial.medpath.com/news/4b7fd1486d1d04ad/recipharm-expands-global-pharmaceutical-development-capabilities-with-strategic-investments 2024-10-03T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ec33aada3a3a5d47/gender-gap-in-heart-disease-women-face-higher-misdiagnosis-risks-and-mortality-rates 2024-10-03T06:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/48bee700c2abcfee/resolution-therapeutics-macrophage-therapy-raises-85-million-labiotech-eu 2024-10-03T06:32:33+00:00 weekly 0.7 https://trial.medpath.com/news/9e1038b98f9b89ef/study-aims-to-resolve-variants-of-uncertain-significance 2024-10-03T05:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/bca13ae2f6696998/high-rates-of-polycythemia-vera-remission-seen-with-ruxolitinib-plus-peg-ifn 2024-10-03T03:27:45+00:00 weekly 0.7 https://trial.medpath.com/news/83f7e257ec868e5a/proscia-launches-ai-powered-pathology-platform-to-accelerate-precision-medicine-research 2024-10-03T01:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/c5e9731796bfb49a/weight-loss-drugs-gene-therapies-clinical-trials-to-watch-right-now-quartz 2024-10-03T00:01:17+00:00 weekly 0.7 https://trial.medpath.com/news/98fa7f5e1e0155cd/fda-fully-revokes-authorization-of-gsk-and-vir-s 2024-10-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9d1ba11a300641f9/breakthrough-t1d-and-integrated-nanotherapeutics-collaborate-to-advance-development 2024-10-02T23:35:22+00:00 weekly 0.7 https://trial.medpath.com/news/3d9e2a843c5a571a/processa-pharmaceuticals-announces-first-patient-dosed-in-phase-2-clinical-trial-of-ngc 2024-10-02T23:22:07+00:00 weekly 0.7 https://trial.medpath.com/news/dda0d748bd8f798a/noraps-phase-2-trial-to-test-noradrenaline-reuptake-inhibitor-atomoxetine-in-psp 2024-10-02T23:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/576884d51992c317/dcisionrt-biosignature-identifies-residual-recurrence-risk-in-her2-3-breast-cancer 2024-10-02T22:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/91c12fb5f586a3c1/fda-grants-ind-for-respirx-inhalable-nicotine-replacement-therapy-pharmacy-times 2024-10-02T22:38:30+00:00 weekly 0.7 https://trial.medpath.com/news/0ab5790d5805ad15/three-outcome-designs-for-external-pilot-trials-with-progression-criteria 2024-10-02T22:34:40+00:00 weekly 0.7 https://trial.medpath.com/news/3804bec5e2ab062e/monogram-technologies-receives-fda-response-for-mbos-tka-system-stock-titan 2024-10-02T22:30:05+00:00 weekly 0.7 https://trial.medpath.com/news/e4b5b1a15614a731/myrtelle-s-canavan-disease-gene-therapy-raav-olig001-aspa-decreases-n 2024-10-02T22:16:51+00:00 weekly 0.7 https://trial.medpath.com/news/2aa41e2eedb4a90f/exploring-the-complexities-of-clinical-oncology-bowdoin-college 2024-10-02T22:11:24+00:00 weekly 0.7 https://trial.medpath.com/news/d6666ef74f1c95c1/erleada-demonstrates-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-compared-to-enzalutamide-in-patients-with-metastatic-castration-sensitive-prostate-cancer 2024-10-02T22:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/9e429423007ab393/radiotherapy-vs-transoral-robotic-surgery-for-oropharyngeal-squamous-cell-carcinoma 2024-10-02T21:58:13+00:00 weekly 0.7 https://trial.medpath.com/news/7ed2eb83cafc6093/aethlon-medical-expands-equity-incentive-plan-by-3-million-shares-investing-com-uk 2024-10-02T21:23:08+00:00 weekly 0.7 https://trial.medpath.com/news/e7ed9dcea35b7af1/september-2024-fda-roundup-key-decisions-drive-oncology-forward 2024-10-02T21:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/f72568f3c9ae6993/clinical-trial-examines-standard-vs-extended-lymph-node-removal-for-muscle-invasive 2024-10-02T21:00:42+00:00 weekly 0.7 https://trial.medpath.com/news/ae377b137f49a2f0/safety-and-efficacy-assessment-of-fecal-microbiota-transplantation-as-an-adjunctive-nature 2024-10-02T20:46:33+00:00 weekly 0.7 https://trial.medpath.com/news/bc64d361ac665907/medulloblastoma-initiative-unveils-latest-impact-report-showcasing-breakthrough-fda 2024-10-02T20:34:23+00:00 weekly 0.7 https://trial.medpath.com/news/ba0d3b0bd3830b81/arcus-biosciences-announces-clinical-trial-collaboration-agreement-to-evaluate-yahoo-finance 2024-10-02T20:32:00+00:00 weekly 0.7 https://trial.medpath.com/news/9e9034051b18d763/fda-finalizes-q-a-guidance-on-electronic-records-in-clinical-trials-raps 2024-10-02T20:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/c9bbc9c0f6ecfea9/acurx-reports-positive-trial-results-for-new-antibiotic-02-10-2024-kursiv-kz 2024-10-02T20:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/3cf2aa557e4ae6dc/biotechnology-company-launches-cancer-vaccine-trial-for-dogs-dvm360 2024-10-02T20:12:40+00:00 weekly 0.7 https://trial.medpath.com/news/11060995b8cc2ab8/tryptase-inhibitor-did-not-significantly-affect-time-to-asthma-exacerbation 2024-10-02T20:04:50+00:00 weekly 0.7 https://trial.medpath.com/news/735f15648b61988b/rice-s-biotech-launch-pad-to-lead-commercialization-of-bioelectrical-implant-treatment-for 2024-10-02T19:55:48+00:00 weekly 0.7 https://trial.medpath.com/news/ca750c2ed91247c9/lecanemab-side-effects-potential-risks-in-cvd-patients-clinical-advisor 2024-10-02T19:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/a371cae7dfe6324c/missouri-is-supporting-research-on-how-magic-mushrooms-can-treat-drug-addiction-with 2024-10-02T19:06:48+00:00 weekly 0.7 https://trial.medpath.com/news/bad85e4c014ff56e/recursion-gets-fda-approval-to-begin-phase-1-trials-of-ai-discovered-cancer-treatment 2024-10-02T18:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/757d55ffc8123700/ninth-circuit-strengthens-fda-authority-to-enforce-drug-regs-against-certain-stem-cell-products 2024-10-02T18:39:10+00:00 weekly 0.7 https://trial.medpath.com/news/35eab0922c65c325/data-supports-approval-of-biosimilar-aflibercept-for-diabetic-macular-edema 2024-10-02T18:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/f1243b30e6193039/the-drug-that-s-helping-the-world-quit-smoking-except-in-america 2024-10-02T18:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/2b6252f3986c3e9f/researchers-develop-insights-into-kras-mutations-in-pancreatic-cancers-medical-xpress 2024-10-02T17:23:46+00:00 weekly 0.7 https://trial.medpath.com/news/c79b0b6a058258ba/anixa-biosciences-seeks-protocol-change-to-enable-repeat-dosing-in-trial-for-ovarian 2024-10-02T17:18:14+00:00 weekly 0.7 https://trial.medpath.com/news/4611c67f3ac4d6ac/hido-technologies-awarded-phase-ii-sbir-grant-by-national-institute-on-aging-nia-for-prweb 2024-10-02T17:01:46+00:00 weekly 0.7 https://trial.medpath.com/news/83edb7112af4a40f/biostem-technologies-initiates-br-ac-dfu-101-clinical-trial-globenewswire 2024-10-02T17:01:31+00:00 weekly 0.7 https://trial.medpath.com/news/3953e0505c78077c/emergex-t-cell-priming-vaccine-candidate-for-betacoronaviruses-selected-by-nih-niaid 2024-10-02T16:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/c81060d04ce81bd3/anti-cancer-antibodies-may-aid-early-melanoma-detection-inside-precision-medicine 2024-10-02T16:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/8e0616f52e4713a1/apalutamide-associated-with-improved-survival-vs-enzalutamide-in-mcspc-urology-times 2024-10-02T16:43:42+00:00 weekly 0.7 https://trial.medpath.com/news/f1f1963f89cb822d/decadine-demonstrates-therapeutic-potential-for-the-treatment-of-myelofibrosis 2024-10-02T16:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/090008403e8dc5a8/conformal-medical-kicks-off-left-atrial-appendage-occlusion-device-trial-massdevice 2024-10-02T16:16:30+00:00 weekly 0.7 https://trial.medpath.com/news/e2368a2eda3c8681/biointellisense-wins-fda-nod-for-biobutton-multi-patient-wearable-monitor-massdevice 2024-10-02T16:16:29+00:00 weekly 0.7 https://trial.medpath.com/news/f22088dbd4687d9e/molecular-and-functional-landscape-of-malignant-serous-effusions-for-precision-oncology 2024-10-02T15:38:01+00:00 weekly 0.7 https://trial.medpath.com/news/e0188cefd234fb6c/weight-loss-from-glp-1-drugs-not-as-robust-in-real-world-settings-forbes 2024-10-02T15:29:38+00:00 weekly 0.7 https://trial.medpath.com/news/d981eaf8e2e6218a/masld-a-disease-in-flux-nature-reviews-gastroenterology-hepatology 2024-10-02T14:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/cd658baa5847bb50/exscientia-outline-robot-and-ai-use-in-drug-discovery-workflow-pharmaceutical-technology 2024-10-02T14:44:16+00:00 weekly 0.7 https://trial.medpath.com/news/b105a1fecd4ba5c9/dr-reddy-s-ties-up-with-gilead-to-manufacture-commercialise-hiv-drug-business-standard 2024-10-02T14:40:05+00:00 weekly 0.7 https://trial.medpath.com/news/d6037c1ceb838ea6/us-fda-authorizes-launch-of-clinical-trial-to-support-new-treatment-development-for-progeria 2024-10-02T14:34:59+00:00 weekly 0.7 https://trial.medpath.com/news/58a6d390a20faa6f/ions-rare-neurology-disorder-candidate-gets-fda-s-fast-track-tag-barchart-com 2024-10-02T14:23:44+00:00 weekly 0.7 https://trial.medpath.com/news/66118011a94b39da/safer-epilepsy-treatment-for-pregnant-women-with-drug-combo-neuroscience-news 2024-10-02T14:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/25e842f728d10ed2/onyda-xr-first-liquid-nonstimulant-for-adhd-now-available-in-us-drug-topics 2024-10-02T14:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/79138f339dcbc040/lymphoplasmacytic-lymphoma-vaccine-leads-to-potential-clinical-benefit-as-early-intervention 2024-10-02T14:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/04b19dfd10767dc3/with-115m-more-triveni-accelerates-immune-drug-work-biopharma-dive 2024-10-02T14:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/aeb2325f81f5e7da/alterity-therapeutics-raises-profile-with-multiple-data-presentations-at-the-international-biospace 2024-10-02T13:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/2e544c89f1684f03/adoptive-cell-therapy-clinical-trials-report-2024-trends 2024-10-02T13:31:15+00:00 weekly 0.7 https://trial.medpath.com/news/dc4791e4d5d8f781/hepatology-month-in-review-september-2024-hcplive 2024-10-02T13:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/d1437aa255a32f27/jaguar-s-diarrhoea-drug-shows-benefit-in-phase-iii-breast-cancer-subgroup 2024-10-02T13:28:23+00:00 weekly 0.7 https://trial.medpath.com/news/8b71bfe1bbdaea78/alzecure-s-acd856-s-effects-to-be-presented-at-alzheimer-s-conference-pharmatimes 2024-10-02T13:27:01+00:00 weekly 0.7 https://trial.medpath.com/news/78536ea55078f11b/oryzon-genomics-fda-aligns-on-phase-iii-bpd-plans-edison-investment-research 2024-10-02T12:56:39+00:00 weekly 0.7 https://trial.medpath.com/news/c383908913819768/kazia-therapeutics-announces-presentation-of-promising-phase-i-data-evaluating 2024-10-02T12:50:54+00:00 weekly 0.7 https://trial.medpath.com/news/bf3187d8877f8dde/bristol-myers-squibb-announces-positive-data-for-sotyktu-in-moderate-to-severe-psoriasis 2024-10-02T12:43:39+00:00 weekly 0.7 https://trial.medpath.com/news/9f71f44c99b830b8/novaliq-and-laboratoires-thea-announce-partnership-and-eu-approval-for-vevizye 2024-10-02T12:40:33+00:00 weekly 0.7 https://trial.medpath.com/news/aa71a58dde680eb8/volastra-therapeutics-granted-fda-fast-track-designation-for-novel-kif18a-inhibitor-in 2024-10-02T12:36:12+00:00 weekly 0.7 https://trial.medpath.com/news/0907d380dc961025/fda-clears-abionic-s-ivd-capsule-psp-for-the-early-detection-of-sepsis-biospace 2024-10-02T12:36:11+00:00 weekly 0.7 https://trial.medpath.com/news/e6796106c6dd5b0d/pds-biotech-announces-36-month-overall-survival-rate-of-globenewswire 2024-10-02T12:22:10+00:00 weekly 0.7 https://trial.medpath.com/news/ffc79acd7b86f621/a-digital-intervention-for-cognitive-deficits-following-covid-19-a-randomized-clinical-trial 2024-10-02T12:15:30+00:00 weekly 0.7 https://trial.medpath.com/news/61380df975a9a8dc/first-patient-dosed-in-phase-3-clinical-trial-of-ugn-103-a-next-generation-mitomycin 2024-10-02T12:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/97377b7d32d9166e/setpoint-medical-receives-fda-s-ide-approval-for-u-s-pilot-study-of-neuroimmune 2024-10-02T12:06:09+00:00 weekly 0.7 https://trial.medpath.com/news/4aaf85f2a259af40/genieus-genomics-announces-completion-of-phase-2-clinical-trial-enrollment-ein-news 2024-10-02T12:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/e712c81d44c98ea9/the-influence-of-simultaneous-posterior-colporrhaphy-and-perineoplasty-on-the-efficiency 2024-10-02T11:34:25+00:00 weekly 0.7 https://trial.medpath.com/news/21d16a51e08888f2/toleranzia-submits-a-clinical-trial-application-cta-for-the-drug-candidate-tol2-for-the-placera 2024-10-02T11:13:10+00:00 weekly 0.7 https://trial.medpath.com/news/fac5bd17a02fec8c/ocugen-to-present-at-the-2024-cell-gene-meeting-on-the-mesa-globenewswire 2024-10-02T10:50:15+00:00 weekly 0.7 https://trial.medpath.com/news/06e1ebe8f58d3dda/amsel-medical-signs-7-45m-phase-iii-sbir-contract-yahoo-finance 2024-10-02T10:49:42+00:00 weekly 0.7 https://trial.medpath.com/news/e3dab97ba094c787/genenta-secures-approval-for-innovative-trial-for-metastatic-renal-cell-cancer-stock-titan 2024-10-02T10:48:21+00:00 weekly 0.7 https://trial.medpath.com/news/7336b67cc1f306da/one-in-three-americans-has-a-dysfunctional-metabolism-clinical-trial-suggests-intermittent 2024-10-02T10:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/acb163142c29b00d/surmodics-receives-fda-510-k-clearance-for-pounce-xl-thrombectomy-system 2024-10-02T09:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/6279098cdb487ed2/fierce-names-insilico-medicine-as-one-of-its-fierce-50-honorees-of-2024-eurekalert 2024-10-02T09:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/c0e7ede503924301/her2-directed-adcs-spread-like-wildfire-across-the-spectrum-of-solid-malignancies 2024-10-02T09:16:16+00:00 weekly 0.7 https://trial.medpath.com/news/656e14efd2339f89/can-flashing-lights-stall-alzheimer-s-what-the-science-shows-nature 2024-10-02T09:16:15+00:00 weekly 0.7 https://trial.medpath.com/news/6c8aefef18c94055/brain-zap-treatment-could-get-arms-hands-moving-after-head-injury 2024-10-02T09:10:52+00:00 weekly 0.7 https://trial.medpath.com/news/1bb786e6c5c22e2b/coffee-water-soda-which-raise-your-odds-for-stroke 2024-10-02T09:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/adffb617d7f0bc00/a-phenocopy-signature-of-tp53-loss-predicts-response-to-chemotherapy 2024-10-02T08:47:29+00:00 weekly 0.7 https://trial.medpath.com/news/74be1e391c911708/spineguard-obtains-fda-clearance-for-commercial-release-of-its-psifguard-new-smart 2024-10-02T08:46:09+00:00 weekly 0.7 https://trial.medpath.com/news/0b0c8028ad32ece0/jlk-s-ai-stroke-solution-receives-fda-approval-businesskorea 2024-10-02T08:43:41+00:00 weekly 0.7 https://trial.medpath.com/news/2c672c0438d1e20f/after-cassava-alzheimer-drug-fiasco-fda-must-protect-patients-stat-news 2024-10-02T08:39:02+00:00 weekly 0.7 https://trial.medpath.com/news/8e01ef8f5211862d/ensysce-biosciences-updates-shareholders-on-clinical-progress-and-financial-status 2024-10-02T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e14a33399ceaa1fb/terrapower-isotopes-brings-actinium-225-to-market 2024-10-02T07:57:10+00:00 weekly 0.7 https://trial.medpath.com/news/27de9392c072662b/pbm-reform-urgently-needed-as-drug-pricing-crisis-deepens-industry-analysis-shows 2024-10-02T07:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/87d8ce9ed580d688/allogeneic-t-cell-therapy-produces-efficacy-at-10-months-in-stage-iv-metastatic-nsclc 2024-10-02T07:12:04+00:00 weekly 0.7 https://trial.medpath.com/news/53a3d48aceeb9983/exact-therapeutics-to-present-at-the-bi-annual-contrast-media-research-cmr-symposium-2024 2024-10-02T06:42:25+00:00 weekly 0.7 https://trial.medpath.com/news/34bc8ab59567e8ea/wuxi-apptec-predicts-shift-from-antibodies-to-peptides-in-radiopharmaceutical-development 2024-10-02T06:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/71328ea71fdfed09/halda-therapeutics-appoints-christian-schade-as-ceo-citybiz 2024-10-02T06:05:58+00:00 weekly 0.7 https://trial.medpath.com/news/10e32faf3e263b01/scope-of-things-trial-planning-skews-conclusions-ai-diversity-help-news-of-the-month 2024-10-02T05:00:09+00:00 weekly 0.7 https://trial.medpath.com/news/95d5c78c74123b7e/phase-ii-basket-trial-of-dual-anti-ctla-4-and-anti-pd-1-blockade-in-rare-tumors 2024-10-02T04:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/92e7e73f0809349e/jazz-pharmaceuticals-inc-latest-stock-news-market-updates 2024-10-02T02:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/351224b3ee370e86/merck-completes-acquisition-of-investigational-bispecific-antibody-therapy-from-curon 2024-10-02T02:28:44+00:00 weekly 0.7 https://trial.medpath.com/news/6c16cd2478a9bdb6/ai-and-community-based-trials-drive-145-increase-in-clinical-trial-engagement-promising-greater-diversity 2024-10-02T01:17:46+00:00 weekly 0.7 https://trial.medpath.com/news/6a186b3c9c0829fa/avmf-stanton-foundation-offering-150000-research-grant 2024-10-02T01:06:46+00:00 weekly 0.7 https://trial.medpath.com/news/e100e7f353905661/thryv-therapeutics-granted-fda-orphan-drug-designation-for-lqt-1213-in-long-qt 2024-10-02T01:01:04+00:00 weekly 0.7 https://trial.medpath.com/news/481f144c3107e032/tnk-stroke-treatment-how-it-works-administration-and-more-medicalnewstoday 2024-10-02T00:44:10+00:00 weekly 0.7 https://trial.medpath.com/news/06af049d3b71268b/nearly-half-of-fda-authorized-ai-tools-may-provide-little-benefit-medical-economics 2024-10-02T00:27:05+00:00 weekly 0.7 https://trial.medpath.com/news/906a6e7b5d4a9ffb/first-in-class-ar-degrader-shows-promise-in-castration-resistant-prostate-cancer-dana-rathkopf 2024-10-02T00:22:12+00:00 weekly 0.7 https://trial.medpath.com/news/77156ab0afa13a8e/roswell-park-radiation-oncologist-highlights-new-insights-on-single-fraction-radiation-for 2024-10-01T23:19:39+00:00 weekly 0.7 https://trial.medpath.com/news/8be1ac3f09fb2562/ascendis-pharma-submits-fda-application-for-expanded-use-of-skytrofa-medwatch 2024-10-01T22:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/de34690ea6567b48/astro-2024-combination-of-nivolumab-immunotherapy-with-radiation-therapy-and-urotoday 2024-10-01T22:27:41+00:00 weekly 0.7 https://trial.medpath.com/news/d46b16beb58c5b76/suicide-attempts-reduced-by-25-with-integrated-primary-care-intervention 2024-10-01T22:25:44+00:00 weekly 0.7 https://trial.medpath.com/news/0ceb7df612cb5151/maze-therapeutics-initiates-phase-1-first-in-human-trial-evaluating-mze782-as-a-potential 2024-10-01T22:17:08+00:00 weekly 0.7 https://trial.medpath.com/news/430ce70c285c5044/bms-986393-shows-first-in-class-potential-in-relapsed-refractory-multiple-myeloma 2024-10-01T21:31:54+00:00 weekly 0.7 https://trial.medpath.com/news/7e00404889651b8c/perimeter-announces-completion-of-patient-enrollment-in-pivotal-clinical-trial-evaluating 2024-10-01T20:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/240f8326ca8cedbb/breast-cancer-patients-denied-precious-time-with-loved-ones-as-new-drug-korserdu-rejected-on-nhs 2024-10-01T20:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/cefc2efe4f686ef6/adaptive-radiotherapy-modality-appears-safe-feasible-in-high-grade-glioma 2024-10-01T19:33:41+00:00 weekly 0.7 https://trial.medpath.com/news/301b88165fb6e7e8/outrage-of-the-month-expanded-fda-approval-of-a-gene-therapy-for-muscular-dystrophy 2024-10-01T19:31:35+00:00 weekly 0.7 https://trial.medpath.com/news/5fbdb79bc149b428/eirion-therapeutics-announces-results-of-first-in-human-clinical-trial-evaluating-ready-to 2024-10-01T19:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/166e965796b6a2e0/ptc-therapeutics-announces-fda-acceptance-for-filing-of-nda-for-sepiapterin-for-pr-newswire 2024-10-01T19:01:49+00:00 weekly 0.7 https://trial.medpath.com/news/a3a7da922ffb8d7b/psilocybin-s-potentially-revolutionary-ability-to-treat-depression-hinges-on-fda-approval 2024-10-01T18:49:03+00:00 weekly 0.7 https://trial.medpath.com/news/56f1b4a7e3ecc1c1/invivyd-announces-u-s-fda-has-updated-the-pemgardatm-eua-fact-sheet-with-accurate 2024-10-01T18:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/79ecf2f8c2b0dc09/cancer-patients-who-experience-cognitive-decline-after-radiation-treatment-for-brain 2024-10-01T17:44:29+00:00 weekly 0.7 https://trial.medpath.com/news/00f78857e962480d/ultrasound-method-linked-with-improved-survival-in-patients-with-crc-liver-metastases 2024-10-01T17:43:02+00:00 weekly 0.7 https://trial.medpath.com/news/763800779bcc1440/pre-operative-prediction-of-bcr-free-survival-with-mrna-variables-in-prostate-cancer-plos-one 2024-10-01T17:40:45+00:00 weekly 0.7 https://trial.medpath.com/news/b9cea7791f49b52b/can-telehealth-help-patients-stick-with-buprenorphinie-for-opioid-addiction-uc-davis-health 2024-10-01T17:39:25+00:00 weekly 0.7 https://trial.medpath.com/news/19ec2b579216de2c/gritstone-bio-reports-positive-interim-phase-2-data-investing-com 2024-10-01T17:26:35+00:00 weekly 0.7 https://trial.medpath.com/news/9500dd93649a60f3/for-the-first-time-a-drug-developed-at-uwm-enters-fda-clinical-trials-letters-science 2024-10-01T17:15:12+00:00 weekly 0.7 https://trial.medpath.com/news/389d93bb006897b0/5-fda-decisions-to-watch-in-the-fourth-quarter-biopharma-dive 2024-10-01T17:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/939de6177e11d819/ember-imlunestrant-in-estrogen-receptor-positive-her2-negative-advanced-breast-cancer 2024-10-01T16:30:10+00:00 weekly 0.7 https://trial.medpath.com/news/1a132c103f4bf291/acumen-and-lonza-expand-collaboration-for-early-alzheimer-s-drug 2024-10-01T16:17:53+00:00 weekly 0.7 https://trial.medpath.com/news/6641eea2c6cc94cb/kailera-therapeutics-emerges-from-stealth-with-400m-for-obesity-drugs-biopharma-dive 2024-10-01T16:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/18b31ae4b2e998ba/repare-therapeutics-announces-phase-1-data-highlighting-camonsertib-in-combination 2024-10-01T16:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/13305b635a5e3235/alzheimer-s-drug-lecanemab-ema-re-examining-marketing-authorisation-euractiv 2024-10-01T15:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/916ec4feb62cae18/glp-1-weight-loss-meds-could-interfere-with-endoscopy-colonoscopy 2024-10-01T15:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/ebffdb4cdd184c1d/researchers-identify-new-therapeutic-approach-to-preventing-cancer-from-spreading-to-the-brain 2024-10-01T15:05:56+00:00 weekly 0.7 https://trial.medpath.com/news/eb979a4ebd7d8bac/is-gene-therapy-the-next-big-step-in-vision-loss-treatment-medicalnewstoday 2024-10-01T15:03:46+00:00 weekly 0.7 https://trial.medpath.com/news/86db2aacaeeb97df/dr-reddy-s-receives-positive-chmp-opinion-from-european-medicines-agency-for-its-bizz-buzz 2024-10-01T14:50:14+00:00 weekly 0.7 https://trial.medpath.com/news/e8d5bfaa7c8a1da3/ron-renaud-s-new-obesity-biotech-kailera-has-400m-to-go-straight-to-phase-3 2024-10-01T14:43:43+00:00 weekly 0.7 https://trial.medpath.com/news/dc60ec32a87c1759/clinical-trials-at-children-s-of-alabama-help-find-the-best-treatments-for-children-with-cancer 2024-10-01T14:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/7447caffc5c1b58e/drones-and-biotechs-are-moving-this-morning-raging-bull 2024-10-01T14:39:05+00:00 weekly 0.7 https://trial.medpath.com/news/f7c77c3aa62c611e/mpox-declared-international-public-health-emergency-as-cases-continue-to-rise 2024-10-01T14:37:32+00:00 weekly 0.7 https://trial.medpath.com/news/9f3fe26f229110d0/targeted-treatment-provides-orr-and-pfs-benefit-in-pretreated-metastatic-solid-tumors 2024-10-01T14:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/c4c2c77f20ec5005/rationale-and-design-of-the-study-to-investigate-the-metabolic-action-of-imeglimin-on 2024-10-01T14:06:49+00:00 weekly 0.7 https://trial.medpath.com/news/982222a0ef9c61da/teva-pharma-launches-octreotide-acetate-for-injectable-suspension-quick-facts 2024-10-01T14:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/80f50f6be1ad5283/ascelia-pharma-s-primary-results-from-phase-iii-study-to-be-presented-at-rsna-conference 2024-10-01T14:01:58+00:00 weekly 0.7 https://trial.medpath.com/news/e6a742acdf14b65e/denifanstat-receives-breakthrough-therapy-designation-for-noncirrhotic-mash-hcplive 2024-10-01T13:56:16+00:00 weekly 0.7 https://trial.medpath.com/news/41b7eb258a8e49cf/sermonix-pharmaceuticals-lasofoxifene-demonstrates-anti-estrogen-therapy-increases 2024-10-01T13:32:55+00:00 weekly 0.7 https://trial.medpath.com/news/16fa14de4b3a06f7/eli-lilly-aims-to-expand-weight-loss-drug-trials-to-those-at-risk-not-just-overweight 2024-10-01T13:13:38+00:00 weekly 0.7 https://trial.medpath.com/news/179287ae003a21f4/mechanism-behind-ulixacaltamide-to-treat-essential-tremor-marcio-souza-neurologylive 2024-10-01T12:49:47+00:00 weekly 0.7 https://trial.medpath.com/news/816b09849499168e/barinthus-bio-completes-enrollment-for-phase-2b-hbv003-globenewswire 2024-10-01T12:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/3f96e300fb9b8eb9/bioatla-announces-upcoming-oral-presentation-at-the-society-globenewswire 2024-10-01T12:03:14+00:00 weekly 0.7 https://trial.medpath.com/news/78100b6de2759743/igm-biosciences-shifts-focus-to-autoimmune-disease-research-amid-staff-layoffs 2024-10-01T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4291b90cd67ce426/chemomab-therapeutics-to-present-at-october-2024-investor-conferences-biospace 2024-10-01T11:55:02+00:00 weekly 0.7 https://trial.medpath.com/news/4841f7ccfcc8dd0c/register-certain-tests-for-phase-3-of-the-dex-z-codes-uhcprovider-com 2024-10-01T11:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/6c9d2f7b93ec605b/cybin-expands-clinical-team-to-support-cyb003-phase-3-program-morningstar 2024-10-01T11:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/bbf5bc7b09242e64/aurobindo-pharma-receives-us-fda-approval-for-an-antibiotics-tablet-ndtv-profit 2024-10-01T11:23:52+00:00 weekly 0.7 https://trial.medpath.com/news/983a01a7966f8046/polypid-enrolls-last-patient-for-planned-unblinded-interim-analysis-in-shield-ii-tipranks 2024-10-01T11:22:52+00:00 weekly 0.7 https://trial.medpath.com/news/22e00c07bb849e35/zilganersen-granted-u-s-fda-fast-track-designation-for-people-living-with-alexander-disease 2024-10-01T11:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/0380a64e67617d7c/edap-announces-first-patients-treated-in-phase-i-ii-study-evaluating-focal-one-robotic 2024-10-01T11:12:40+00:00 weekly 0.7 https://trial.medpath.com/news/2627b9103502a890/cytosorbents-submits-drugsorb-atr-marketing-application-to-globenewswire 2024-10-01T11:05:07+00:00 weekly 0.7 https://trial.medpath.com/news/962dd4f722013529/shattuck-labs-provides-company-update-and-announces-sl-325-globenewswire 2024-10-01T10:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/abba30b03c12e70f/spima-therapeutics-starts-with-global-licence-agreement-european-biotechnology 2024-10-01T10:26:31+00:00 weekly 0.7 https://trial.medpath.com/news/9b30e50a002300e3/cel-sci-selects-ergomed-as-cro-as-it-gears-up-for-confirmatory-fda-registration-study 2024-10-01T10:25:07+00:00 weekly 0.7 https://trial.medpath.com/news/1a2e7bcf26d457dc/a-review-of-recent-clinical-trials-to-evaluate-disease-modifying-therapies-in-the-treatment-frontiers 2024-10-01T09:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/d6e296ae25ea0381/spago-nanomedical-in-new-phase-with-full-focus-on-the-tumorad-program 2024-10-01T09:51:02+00:00 weekly 0.7 https://trial.medpath.com/news/6b7ecb10943dd651/sacituzumab-govitecan-in-hr-her2-metastatic-breast-cancer-the-randomized-phase-3 2024-10-01T09:50:19+00:00 weekly 0.7 https://trial.medpath.com/news/6ecba3aacd746570/kezar-life-sciences-suspends-subject-enrolment-in-trial-of-lupus-nephritis-drug 2024-10-01T09:46:08+00:00 weekly 0.7 https://trial.medpath.com/news/3af00e9f1b8c67d0/black-white-cancer-patients-now-benefit-equally-from-cord-blood-therapy 2024-10-01T09:10:57+00:00 weekly 0.7 https://trial.medpath.com/news/aaed47177da9171a/covid-shot-lowers-your-odds-for-covid-linked-heart-trouble 2024-10-01T09:10:14+00:00 weekly 0.7 https://trial.medpath.com/news/8cdd6e868b9e1310/arun-upadhyay-phd-on-results-from-ird-gene-therapy-ocu400-s-phase-1-2-trial 2024-10-01T08:47:41+00:00 weekly 0.7 https://trial.medpath.com/news/ea001e88cde94365/study-links-conversion-practices-to-increased-mental-health-risks-in-lgbtq-adults 2024-10-01T08:13:07+00:00 weekly 0.7 https://trial.medpath.com/news/4ed649d307dc13c8/incannex-healthcare-inc-reports-fiscal-full-year-2024-financial-results-and-business-updates 2024-10-01T08:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/245c5c5a50efa144/sequana-medical-announces-h1-2024-results-and-provides-business-update-biospace 2024-10-01T07:58:45+00:00 weekly 0.7 https://trial.medpath.com/news/bb1656048bf71e5e/cartherics-raises-over-15-million-in-oversubscribed-private-financing-round-to-advance 2024-10-01T07:58:44+00:00 weekly 0.7 https://trial.medpath.com/news/b07358e0f16b5219/drug-shortages-in-australia-highlight-critical-need-to-include-pregnant-women-in-clinical-trials 2024-10-01T06:26:45+00:00 weekly 0.7 https://trial.medpath.com/news/823c993ba8813b96/survey-reveals-low-intent-for-respiratory-vaccinations-among-us-adults-for-2024-2025-season 2024-10-01T05:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/6e100def8ac1c24a/study-highlights-promising-new-treatment-option-for-patients-with-treatment-resistant 2024-10-01T05:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/f17459cb44e54a6c/key-medical-conferences-set-to-shape-biopharma-industry-in-2025 2024-10-01T04:34:00+00:00 weekly 0.7 https://trial.medpath.com/news/9d156d9b73ba5b0f/talapro-2-analysis-talazoparib-enzalutamide-combo-in-pretreated-mcrpc-neeraj-agarwal 2024-10-01T04:25:33+00:00 weekly 0.7 https://trial.medpath.com/news/c8407886bdd71178/avera-medical-minute-avera-offers-phase-1-clinical-trials-for-cancer-patients-dakota-news-now 2024-10-01T03:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/e2577c45669fdab8/msd-terminates-phase-ii-trials-for-alzheimer-s-drug-due-to-liver-toxicity-msn 2024-10-01T02:53:22+00:00 weekly 0.7 https://trial.medpath.com/news/76285439e5cbc46a/zilganersen-granted-u-s-fda-fast-track-designation-for-people-living-with-alexander-disease 2024-10-01T02:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/3d16b4562b88d712/llms-set-to-transform-clinical-trial-management-through-enhanced-irt-systems 2024-10-01T00:49:02+00:00 weekly 0.7 https://trial.medpath.com/news/19fda7fd58c86e5d/a-phase-i-study-of-iag933-in-patients-with-advanced 2024-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/940a76023b69554e/doxycycline-prophylaxis-for-the-prevention-of-sexually 2024-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8cf25c953d6e0d71/sapience-therapeutics-enrolls-first-patient-in-phase-2-study-of-st316 2024-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d2bfe5f73d9bca3f/sonrotoclax-dexamethasone-combo-is-tolerable-generates-deep-responses-in-t-11-14-r 2024-09-30T23:48:59+00:00 weekly 0.7 https://trial.medpath.com/news/c82fc0d95c8b406a/clinuvel-files-canadian-new-drug-submission-for-scenesse-r-in-epp-globenewswire 2024-09-30T23:11:21+00:00 weekly 0.7 https://trial.medpath.com/news/e03dd6e38b9df7bf/hypofractionated-rt-after-mastectomy-is-noninferior-to-soc-in-breast-cancer 2024-09-30T23:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/6317a2392d2228b3/redhill-announces-new-u-s-coronavirus-patent-for-opaganib-valid-through-2041 2024-09-30T23:01:08+00:00 weekly 0.7 https://trial.medpath.com/news/f3ca3b7051e49fb7/buy-recommendation-for-bridgebio-pharma-amidst-promising-drug-trials-and-upcoming 2024-09-30T22:31:35+00:00 weekly 0.7 https://trial.medpath.com/news/6aa2264a4a4c65ce/legend-biotech-reiterates-stock-target-overweight-on-phase-iii-data-investing-com 2024-09-30T22:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/01af8d8a2a4e58dc/struggling-to-find-an-effective-depression-treatment-the-reporter-uab 2024-09-30T22:10:57+00:00 weekly 0.7 https://trial.medpath.com/news/0d24d0ee99310d49/roche-turns-to-a-startup-in-search-for-new-breast-cancer-drugs-biopharma-dive 2024-09-30T22:06:11+00:00 weekly 0.7 https://trial.medpath.com/news/c6bc4953959835f9/america-s-nobel-goes-to-a-power-couple-who-made-a-startling-discovery-about-hiv 2024-09-30T22:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/82e79f14c5d06230/university-awarded-12-million-to-further-develop-opioid-use-disorder-drug 2024-09-30T21:51:21+00:00 weekly 0.7 https://trial.medpath.com/news/897fc981931cb526/neurocrine-biosciences-s-crinecerfont-is-set-to-transform-the-congenital-adrenal-pr-newswire 2024-09-30T21:38:25+00:00 weekly 0.7 https://trial.medpath.com/news/07b1f52cb44c1a47/ucsf-radiation-oncologist-honored-for-prostate-cancer-care-and-research-newswise 2024-09-30T21:18:25+00:00 weekly 0.7 https://trial.medpath.com/news/be6926d736bb95da/trial-supports-radiotherapy-and-cisplatin-remaining-as-the-standard-of-care-for-p16 2024-09-30T21:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/1ef53d0697f20719/triplet-vs-soc-explored-in-metastatic-prostate-cancer-targeted-oncology 2024-09-30T21:06:03+00:00 weekly 0.7 https://trial.medpath.com/news/4f1cba3f7e9edc52/women-in-medicine-month-celebrating-women-advancing-radiology 2024-09-30T21:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/2a9d1d80c0c8d295/study-time-restricted-eating-may-improve-health-of-adults-with-metabolic-syndrome 2024-09-30T21:00:19+00:00 weekly 0.7 https://trial.medpath.com/news/fb75ed92b77bee26/novel-pet-imaging-agent-earns-fast-track-status-for-psma-prostate-cancer 2024-09-30T20:24:45+00:00 weekly 0.7 https://trial.medpath.com/news/c653420273517eb4/merus-announces-first-patient-dosed-in-liger-hn1-a-phase-3-trial-evaluating 2024-09-30T20:16:13+00:00 weekly 0.7 https://trial.medpath.com/news/b4d3a930add29b67/standard-chemoradiation-outperforms-de-intensified-treatments-in-hpv-associated-news-medical 2024-09-30T19:35:39+00:00 weekly 0.7 https://trial.medpath.com/news/7c885bb24d4256e4/rheumatoid-arthritis-study-ids-macrophages-that-could-hasten-diagnosis-treatment 2024-09-30T19:26:26+00:00 weekly 0.7 https://trial.medpath.com/news/841f7670a87b2300/outpatient-car-t-therapy-shows-promise-for-treating-lymphoma-patients-news-medical 2024-09-30T19:19:29+00:00 weekly 0.7 https://trial.medpath.com/news/282af59d6a69afd0/phase-3-real-world-data-show-deucravacitinib-efficacious-for-scalp-overall-psoriasis 2024-09-30T19:03:07+00:00 weekly 0.7 https://trial.medpath.com/news/7403db9fb070f14c/route-66-spore-grant-to-study-uterine-cancers-unm-health-sciences-center 2024-09-30T18:52:05+00:00 weekly 0.7 https://trial.medpath.com/news/25cd83b89ebea080/bristol-myers-beats-6-4-billion-lawsuit-over-delayed-cancer-drug-the-mighty-790-kfgo 2024-09-30T18:43:39+00:00 weekly 0.7 https://trial.medpath.com/news/c5b85fa5b319282d/pi-cardia-receives-fda-market-clearance-for-shortcuttm-biospace 2024-09-30T18:33:19+00:00 weekly 0.7 https://trial.medpath.com/news/df935c8207f783c2/walden-biosciences-fully-enrolls-first-cohort-in-phase-2-basket-study-of-wal0921-in-biospace 2024-09-30T18:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/50195753ebe59a75/clinical-efficacy-of-endostar-continuous-infusion-combined-with-concurrent-frontiers 2024-09-30T18:01:12+00:00 weekly 0.7 https://trial.medpath.com/news/9aa85b29b593fd3a/from-the-esmo-congress-2024-nature-reviews-clinical-oncology 2024-09-30T17:52:31+00:00 weekly 0.7 https://trial.medpath.com/news/5d0051599dcef826/astro-2024-quality-of-life-in-patients-enrolled-in-a-randomized-clinical-trial-evaluating 2024-09-30T17:28:28+00:00 weekly 0.7 https://trial.medpath.com/news/69e3787fa26fa79b/2-year-study-affirms-bimekizumab-s-efficacy-in-hidradenitis-suppurativa 2024-09-30T17:21:18+00:00 weekly 0.7 https://trial.medpath.com/news/d33a3ad49a2644b9/kras-inhibitors-market-new-treatments-are-set-to-change-cancer-care-delveinsight 2024-09-30T17:16:56+00:00 weekly 0.7 https://trial.medpath.com/news/fc7b9d52f0b26339/exploiting-the-role-of-csf-nfl-chit1-and-mir-181b-as-potential-diagnostic-and-prognostic 2024-09-30T17:14:39+00:00 weekly 0.7 https://trial.medpath.com/news/6b0e25981f1ba3ef/ocuphire-pharma-releases-results-from-mira-2-and-mira-3-clinical-trials-for-phentolamine 2024-09-30T17:01:35+00:00 weekly 0.7 https://trial.medpath.com/news/b0208ba8813dee7c/biopharma-partnering-monthly-update-august-2024-taylor-wessing 2024-09-30T16:55:53+00:00 weekly 0.7 https://trial.medpath.com/news/657e8ca19e87bb7b/migraine-drug-could-help-prevent-the-overuse-of-painkillers-miriam-stoppard-the-mirror 2024-09-30T16:47:13+00:00 weekly 0.7 https://trial.medpath.com/news/12dd155aca1d242f/a-multi-center-randomized-double-blind-sham-stimulation-controlled-study-of-transcranial 2024-09-30T16:39:29+00:00 weekly 0.7 https://trial.medpath.com/news/9cfeb30874a47b07/prescribing-antipsychotics-in-patients-with-dementia-what-clinicians-should-know 2024-09-30T16:38:38+00:00 weekly 0.7 https://trial.medpath.com/news/a377a603a57714a6/updated-findings-with-belzutifan-in-von-hippel-lindau-disease-associated-cns 2024-09-30T16:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/085ecef4155dd326/astro-2024-bladder-preservation-a-modern-choice-for-patients-urotoday 2024-09-30T16:14:18+00:00 weekly 0.7 https://trial.medpath.com/news/b764ba912b5b13b2/nrx-100-ketamine-reaches-stability-milestone-contract-pharma 2024-09-30T16:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/dc547704941d2822/astro-2024-strategies-and-evidence-for-sabr-in-rcc-urotoday 2024-09-30T15:57:36+00:00 weekly 0.7 https://trial.medpath.com/news/18a9a69517b20f6d/screening-for-helicobacter-pylori-to-prevent-gastric-cancer-a-pragmatic-randomized-clinical-trial 2024-09-30T15:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/d4e8c7587a394fd3/lanifibranor-may-promote-liver-gains-seen-in-phase-3-mash-trial 2024-09-30T15:50:34+00:00 weekly 0.7 https://trial.medpath.com/news/10b86231fa8182a2/nih-fast-track-grant-for-novel-therapeutic-to-treat-glioblastoma-awarded-to-rosalind 2024-09-30T15:47:32+00:00 weekly 0.7 https://trial.medpath.com/news/0b6182f9c742f344/mytomorrows-and-curelgmd2i-partnership-to-improve-access-to-clinical-trials-for-limb 2024-09-30T15:43:24+00:00 weekly 0.7 https://trial.medpath.com/news/68c6082172b4e3a9/siemens-healthineers-receives-fda-premarket-approval-for-3d-portion-of-mammography-system 2024-09-30T15:33:20+00:00 weekly 0.7 https://trial.medpath.com/news/953901a140dea6c2/opinion-goal-is-to-reverse-paralysis-if-washington-doesn-t-get-in-way-hartford-courant 2024-09-30T15:30:16+00:00 weekly 0.7 https://trial.medpath.com/news/217b57ffe964199f/sage-therapeutics-swot-analysis-cns-drug-maker-s-stock-faces-pipeline-hurdles 2024-09-30T15:18:24+00:00 weekly 0.7 https://trial.medpath.com/news/b0858c9fa9bd90c0/tumor-hypoxia-on-18f-fluoromisonidazole-positron-emission-tomography-and-distant 2024-09-30T15:18:23+00:00 weekly 0.7 https://trial.medpath.com/news/9c220a53c9f9376c/positive-phase-2a-data-suggest-disease-modifying-potential-of-cnp-104-in-pbc-hcplive 2024-09-30T15:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/c0aaaf748de6ecc7/key-reasons-behind-surge-in-semaglutide-usage-european-pharmaceutical-manufacturer 2024-09-30T15:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/f24cb6e5fb2fe9e4/neoadjuvant-therapy-trumps-surgery-in-nsclc-debate-cancer-network 2024-09-30T14:52:51+00:00 weekly 0.7 https://trial.medpath.com/news/ffbe199eaf23aa97/uc-cancer-center-experts-present-research-at-astro-2024-university-of-cincinnati 2024-09-30T14:52:50+00:00 weekly 0.7 https://trial.medpath.com/news/33723fcd4a04949e/a-standing-platform-for-cancer-drug-development-using-ctdna-based-evidence-of-recurrence-nature 2024-09-30T14:50:23+00:00 weekly 0.7 https://trial.medpath.com/news/027fefdd82337e53/arcturus-covid-19-vaccine-triggers-enhanced-immune-response 2024-09-30T14:49:25+00:00 weekly 0.7 https://trial.medpath.com/news/61e739db5f1b9b94/tenax-therapeutics-inc-initiation-of-research-coverage-william-blair 2024-09-30T14:43:11+00:00 weekly 0.7 https://trial.medpath.com/news/3c38b7c48af6861c/the-evolving-treatment-landscape-for-alzheimer-s-technology-networks 2024-09-30T14:42:20+00:00 weekly 0.7 https://trial.medpath.com/news/0b07dd460146eac9/zydus-life-shares-gain-1-today-after-us-fda-approves-cancer-drug-worth-870-million 2024-09-30T14:13:37+00:00 weekly 0.7 https://trial.medpath.com/news/a19052626b81a20d/shorter-course-of-breast-cancer-radiation-won-t-affect-breast-reconstruction 2024-09-30T14:09:39+00:00 weekly 0.7 https://trial.medpath.com/news/a285a3f66225efe2/trial-shows-timing-matters-when-adding-immunotherapy-to-chemoradiation-for-limited-stage 2024-09-30T14:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/d7450c65e7df7e26/memed-s-diagnostic-reduces-antibiotic-overuse-in-us-trial-inside-precision-medicine 2024-09-30T13:56:10+00:00 weekly 0.7 https://trial.medpath.com/news/3512775f2da8d461/september-30-2024-new-guide-from-nih-collaboratory-promotes-health-equity-in 2024-09-30T13:47:02+00:00 weekly 0.7 https://trial.medpath.com/news/6c26964dff5c12be/ascendis-pharma-announces-submission-of-supplemental-biologics-license-application-to 2024-09-30T13:34:49+00:00 weekly 0.7 https://trial.medpath.com/news/d0f4c9c626b92cc4/vaping-addiction-drug-developer-achieve-to-sell-up-to-50-million-of-stock-kursiv-kz 2024-09-30T13:33:20+00:00 weekly 0.7 https://trial.medpath.com/news/bd9abb13c41e4630/bay-area-surfer-scientologist-and-billionaire-is-tackling-one-of-medicine-s-toughest-problems 2024-09-30T13:19:57+00:00 weekly 0.7 https://trial.medpath.com/news/dd832de4cb6e6a8e/accelerate-diagnostics-announces-fda-clearance-of-its-accelerate-arctm-system 2024-09-30T13:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/c2d52436aaec9926/catching-up-with-synchron-s-tom-oxley-on-the-path-to-a-pivotal-trial 2024-09-30T13:16:31+00:00 weekly 0.7 https://trial.medpath.com/news/ecd4071875be6807/study-examining-use-of-nalmefene-hci-injection-for-opioid-overdose-reversal-in 2024-09-30T13:13:35+00:00 weekly 0.7 https://trial.medpath.com/news/345b3d6f9744b1ef/bioai-arbele-partner-to-advance-predictive-ai-models-in-oncology-clinical-trials 2024-09-30T13:11:17+00:00 weekly 0.7 https://trial.medpath.com/news/7551064ad5669f0d/penn-state-college-of-medicine-beat-childhood-cancer-research-consortium-and-four 2024-09-30T13:10:05+00:00 weekly 0.7 https://trial.medpath.com/news/fdb95e123c2ede46/madrigal-pharmaceuticals-announces-publication-of-positive-health-related-quality-of-life 2024-09-30T13:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/44b826922f01b867/inmune-bio-inc-completes-enrollment-for-phase-2-trial-in-early-alzheimer-s-disease 2024-09-30T13:05:41+00:00 weekly 0.7 https://trial.medpath.com/news/cbf5eeb8d6e4fbcb/could-we-prevent-asthma-in-young-allergic-children-boston-children-s-answers 2024-09-30T13:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/444d57d46f5b4e69/medicinova-to-support-nih-funded-expanded-access-clinical-globenewswire 2024-09-30T13:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/e7c3529d96839d79/mitsubishi-tanabe-pharma-america-presents-open-label-extension-outcomes-and-pr-newswire 2024-09-30T13:02:41+00:00 weekly 0.7 https://trial.medpath.com/news/3577b5341bed5736/nanoviricides-prepares-for-phase-ii-trials-for-antiviral-nv-387-nyse-a-nnvc 2024-09-30T13:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/c8bb62cf233a2d25/breakthrough-in-the-fight-against-superbacteria-by-a-hungarian-research-team 2024-09-30T12:47:42+00:00 weekly 0.7 https://trial.medpath.com/news/cba7156fd6e2722c/advancing-clinical-basic-clinical-research-exploring-novel-immunotargets-for-ovarian-cancer 2024-09-30T12:45:30+00:00 weekly 0.7 https://trial.medpath.com/news/e84341dcf69e0f20/altimmune-completes-enrollment-in-phase-2b-impact-trial-of-pemvidutide-in-metabolic 2024-09-30T12:41:42+00:00 weekly 0.7 https://trial.medpath.com/news/9aa33a0222cd4a5a/windtree-announces-positive-phase-2b-topline-clinical-globenewswire 2024-09-30T12:36:30+00:00 weekly 0.7 https://trial.medpath.com/news/9b08375d33b92a0b/new-3-year-skeletal-dynamics-data-for-adults-with-hypoparathyroidism-treated-with-stock-titan 2024-09-30T12:34:52+00:00 weekly 0.7 https://trial.medpath.com/news/5b7cb8be53078d5d/nervgen-pharma-provides-update-on-phase-1b-2a-clinical-trial-of-nvg-291-in-spinal-cord-injury 2024-09-30T12:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/81df4a5eda9ec969/aeon-biopharma-announces-positive-outcome-from-fda-biosimilar-advisory-meeting 2024-09-30T12:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/0471160bbbee93b7/perfluorohexyloctane-ophthalmic-solution-for-dry-eye-disease-pooled-analysis-of-two-phase 2024-09-30T12:18:17+00:00 weekly 0.7 https://trial.medpath.com/news/1b3f3782d67a76ba/precision-biosciences-submits-first-clinical-trial-applications-to-initiate-phase-1-trial-biospace 2024-09-30T12:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/341f0656d12b31c6/the-targeted-pulse-nkt2152-sparks-excitement-in-rcc-amivantamab-chemotherapy 2024-09-30T12:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/02194c3793636555/adaptive-research-announces-it-has-begun-enrolling-patients-in-aribio-s-phase-3-polaris 2024-09-30T12:16:17+00:00 weekly 0.7 https://trial.medpath.com/news/b9ad2dc754c23954/calidi-biotherapeutics-announces-fda-clearance-of-the-globenewswire 2024-09-30T12:14:32+00:00 weekly 0.7 https://trial.medpath.com/news/d6c679db03d1215d/neurobo-pharmaceuticals-announces-positive-top-line-data-from-the-sad-part-1-of-its 2024-09-30T12:04:36+00:00 weekly 0.7 https://trial.medpath.com/news/ddd9e9f8996f1055/family-heart-foundation-launches-free-at-home-lipid-screening-program-to-combat-cardiovascular-disease 2024-09-30T12:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/9f8ba99118d33f2e/dana-farber-cancer-institute-raises-more-than-2-billion-in-record-breaking-fundraising 2024-09-30T11:43:22+00:00 weekly 0.7 https://trial.medpath.com/news/d68771c64d60c86d/geneditbio-secures-strategic-investment-from-gobi-partners-gba-to-accelerate 2024-09-30T11:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/d25cea3aeff40ad6/bridgebio-completes-enrollment-of-fortify-phase-3-globenewswire 2024-09-30T11:33:37+00:00 weekly 0.7 https://trial.medpath.com/news/0cb1d50b9ea45097/biohaven-initiates-pivotal-trial-of-novel-investigational-drug-for-treatment-of-migraine 2024-09-30T11:32:34+00:00 weekly 0.7 https://trial.medpath.com/news/99b1bbb7c49218b7/national-institutes-of-health-study-finds-no-reliable-biomarkers-exist-for-long-covid 2024-09-30T11:29:08+00:00 weekly 0.7 https://trial.medpath.com/news/35f8a41d45b81298/moderna-announces-first-participant-dosed-in-pivotal-phase-3-trial-of-investigational 2024-09-30T11:17:12+00:00 weekly 0.7 https://trial.medpath.com/news/91f7ffe6867740a0/2-minute-medicine-rewind-september-30-2024 2024-09-30T11:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/45baf54d8fd8e038/biotech-stocks-facing-fda-decision-in-october-2024-rttnews 2024-09-30T11:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/c46c903d8753857c/tonix-pharmaceuticals-announces-participation-in-endpoints-globenewswire 2024-09-30T11:01:41+00:00 weekly 0.7 https://trial.medpath.com/news/3d66f6e0df8295d1/self-management-support-program-delivered-in-the-sub-acute-phase-after-traumatic-injury 2024-09-30T10:39:05+00:00 weekly 0.7 https://trial.medpath.com/news/56b70c90bbc19a00/nanoviricides-inc-has-filed-its-annual-report-broad-spectrum-antiviral-nv-387-stock-titan 2024-09-30T10:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/efc844c8881fabf6/primary-endpoint-met-in-phase-3-comparative-clinical-study-of-perjeta-r-pertuzumab 2024-09-30T10:18:55+00:00 weekly 0.7 https://trial.medpath.com/news/beca50a487e29de1/grunenthal-appoints-dr-jan-adams-as-chief-commercial-officer 2024-09-30T10:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/a7baedf4a4bf270f/pharmaust-limited-issues-new-shares-advances-als-treatment-tipranks-com 2024-09-30T09:34:58+00:00 weekly 0.7 https://trial.medpath.com/news/496d81c2c4ce880e/european-commission-approves-yuvanci-r-single-tablet-globenewswire 2024-09-30T09:16:31+00:00 weekly 0.7 https://trial.medpath.com/news/64e153f58f9c9635/synthetic-thc-may-calm-agitation-in-alzheimer-s-patients 2024-09-30T09:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/866bf2f11b1703e3/role-of-the-screening-with-coronary-computed-tomography-angiography-on-lipid-trials-journal 2024-09-30T08:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/6f900c4efbd84092/a-decade-of-pd-1-inhibitors-keytruda-and-opdivo-transform-global-cancer-treatment-landscape 2024-09-30T07:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/dd6b25beb5ade952/medicines-regulators-weigh-hope-and-hype-with-new-alzheimer-s-drugs-swissinfo 2024-09-30T07:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/694720a693b7ead7/doer-biologics-announces-first-patient-dosed-in-phase-2-study-of-dr10624-for-treatment 2024-09-30T07:19:07+00:00 weekly 0.7 https://trial.medpath.com/news/e08240d721828458/sifi-announces-allowance-of-patent-on-polihexanide-for-europe-and-commercial-launch-of 2024-09-30T07:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/5a608a26ac4fd773/identifying-biomarkers-for-treatment-of-uveal-melanoma-by-t-cell-engager-using-a-qsp-model 2024-09-30T06:37:57+00:00 weekly 0.7 https://trial.medpath.com/news/f75ef5f884052d39/ai-solutions-show-promise-in-combating-pharmacist-burnout-and-enhancing-patient-care 2024-09-30T06:36:29+00:00 weekly 0.7 https://trial.medpath.com/news/65da67bf3b2f0605/modalis-therapeutics-fda-grants-rare-pediatric-disease-designation-to-mdl-101-for-the 2024-09-30T06:24:27+00:00 weekly 0.7 https://trial.medpath.com/news/ecd85fe8421a36be/modalis-therapeutics-fda-grants-rare-pediatric-disease-designation-to-mdl-101-for-the 2024-09-30T06:21:47+00:00 weekly 0.7 https://trial.medpath.com/news/0bef60512386fc50/pharmacokinetics-and-pharmacogenomics-of-ribociclib-in-black-patients-with-metastatic 2024-09-30T06:16:25+00:00 weekly 0.7 https://trial.medpath.com/news/41e1194f97dad5ae/photocure-partner-asieris-unveils-cevira-apl-1702-phase-iii-subgroup-analysis-by-age 2024-09-30T06:05:07+00:00 weekly 0.7 https://trial.medpath.com/news/ea0e1bb8b26f778a/verona-pharma-to-present-six-analyses-of-the-phase-3-enhance-studies-in-copd-at-chest-2024 2024-09-30T06:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/5befde95e7d33136/lexaria-receives-independent-review-board-approval-to-begin-human-pilot-study-3 2024-09-30T06:03:09+00:00 weekly 0.7 https://trial.medpath.com/news/9d5cf8ee081fcb15/cinclus-pharma-completes-imp-manufacturing-for-phase-iii-marketscreener 2024-09-30T05:56:24+00:00 weekly 0.7 https://trial.medpath.com/news/1d110c83ef95520b/akeso-s-cadonilimab-receives-second-indication-approval-from-nmpa-for-first-line 2024-09-30T05:48:12+00:00 weekly 0.7 https://trial.medpath.com/news/263cb757f33ef4b4/veteran-tennessee-pharmacist-reflects-on-45-years-of-community-service-and-industry-evolution 2024-09-30T05:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/ddc887bf4d1665e8/experts-highlight-critical-treatment-gaps-in-metastatic-colorectal-cancer-management 2024-09-30T05:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/dade88783d131beb/closer-to-us-commercialisation-ebr-achieves-major-fda-milestone-stockhead 2024-09-30T05:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/e10400fac8ac2885/ai-revolutionizes-healthcare-economics-transforming-clinical-trials-and-value-assessment 2024-09-30T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/81759c450ebeaa59/fda-action-alert-biofrontera-bms-and-zealand-biospace 2024-09-30T04:21:48+00:00 weekly 0.7 https://trial.medpath.com/news/8d01120eb334ec2c/jeil-pharm-launches-jaqbo-its-1st-in-house-drug-in-korea-s-1-billion-peptic-ulcer-market 2024-09-30T03:57:24+00:00 weekly 0.7 https://trial.medpath.com/news/49511d1e2b15ceab/duke-nus-study-proposes-new-heart-failure-treatment-targeting-abnormal-hormone-activity 2024-09-30T03:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/0be84da0b1bcc520/percheron-therapeutics-completes-toxicology-study-for-avicursen-ahead-of-us-fda-discussions 2024-09-30T02:42:28+00:00 weekly 0.7 https://trial.medpath.com/news/28eaa31a62d50d95/valerio-therapeutics-expands-antibody-development-capabilities-with-emglev-therapeutics-acquisition 2024-09-30T02:38:12+00:00 weekly 0.7 https://trial.medpath.com/news/62859de27e56a058/up-manila-researchers-unveil-promising-ampalaya-tablet-for-type-2-diabetes 2024-09-30T02:07:59+00:00 weekly 0.7 https://trial.medpath.com/news/9b66287730c5e13c/mesoblast-to-raise-50m-from-top-shareholder-for-product-launch-capital-brief 2024-09-30T00:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/a6f6b17967f572e0/cutia-therapeutics-completes-phase-ii-trial-tipranks-com 2024-09-30T00:11:13+00:00 weekly 0.7 https://trial.medpath.com/news/c48ea9644bde555a/medidata-clinches-two-excellence-awards-for-innovative-clinical-trial-solutions 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d2369433dfe8d06f/irlab-completes-patient-enrollment-in-phase-iib-study-of-pirepemat-for-parkinson-s-disease 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dd3a403776d20b18/merus-announces-fda-approval-of-bizengri-r 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a5003a4303f97901/histone-deacetylase-inhibition-enhances-extracellular-vesicles-from-muscle-to-promote 2024-09-29T23:48:16+00:00 weekly 0.7 https://trial.medpath.com/news/c01ae0034285901c/initial-results-of-a-phase-2-trial-of-stereotactic-body-radiation-therapy-hormone-androgen 2024-09-29T23:27:21+00:00 weekly 0.7 https://trial.medpath.com/news/cd971ab6232f85fe/bladder-adjuvant-radiotherapy-bart-acute-and-late-toxicity-from-a-phase-iii-multicenter 2024-09-29T23:27:19+00:00 weekly 0.7 https://trial.medpath.com/news/f3f99a70db7fbd4b/astro-2024-post-prostatectomy-linac-based-ultrahypofractionated-radiotherapy-for-urotoday 2024-09-29T23:27:16+00:00 weekly 0.7 https://trial.medpath.com/news/d61e0e69ffc4a4bd/astro-2024-integrating-novel-therapeutics-with-trimodal-therapy-tmt-urotoday 2024-09-29T23:27:14+00:00 weekly 0.7 https://trial.medpath.com/news/b652157fd6b7a5ec/astro-2024-the-space-time-continuum-in-metastatic-castration-sensitive-prostate-cancer 2024-09-29T23:27:13+00:00 weekly 0.7 https://trial.medpath.com/news/4ac817ce47a27ae7/the-alarm-s-mike-peters-says-it-s-incredible-as-he-issues-huge-cancer-update-the-mirror 2024-09-29T23:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/038a16334ae51762/potential-of-device-assisted-therapy-for-advanced-stage-parkinson-disease-david-devos-md-phd 2024-09-29T23:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/7fd81108bce97f9e/blockchain-technology-emerges-as-key-weapon-against-200b-counterfeit-drug-market 2024-09-29T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ba18a2e893c2ab20/people-who-experience-side-effects-from-cranial-radiation-therapy-may-recover-full 2024-09-29T21:18:23+00:00 weekly 0.7 https://trial.medpath.com/news/f34644d00636f856/and-high-risk-localized-prostate-cancer-results-from-the-getug-14-randomized-phase-iii-trial 2024-09-29T21:15:57+00:00 weekly 0.7 https://trial.medpath.com/news/c55f2a1b3eebb784/apac-clinical-services-market-set-to-reach-140-billion-by-2031-as-region-emerges-as-trial-powerhouse 2024-09-29T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2fe5bc5240f875be/pbt-imrt-provide-similar-patient-reported-outcomes-for-prostate-cancer-at-5-years 2024-09-29T19:16:45+00:00 weekly 0.7 https://trial.medpath.com/news/74b5c77dbaa9c805/wall-street-swot-editas-medicine-stock-faces-challenges-in-competitive-gene-editing-market 2024-09-29T17:27:39+00:00 weekly 0.7 https://trial.medpath.com/news/59de3ae624d7c6c9/radiopharmaceutical-therapy-offers-promise-for-people-with-tough-to-treat-meningioma-brain-tumors 2024-09-29T17:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/0beef9ac7bdbb448/bayer-submits-supplemental-new-drug-application-to-usfda-seeking-expanded-indication 2024-09-29T16:56:59+00:00 weekly 0.7 https://trial.medpath.com/news/e799994ba5e3a06d/not-a-placebo-study-finds-meditation-offers-genuine-pain-relief-sciencealert 2024-09-29T16:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/6d3b536cb7cd0e89/first-interim-results-from-fine-real-a-prospective-non-interventional-phase-4-study 2024-09-29T15:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/8b3513649fd582ee/prior-local-therapy-does-not-impact-mcrpc-survival-with-arpi-treatment-urology-times 2024-09-29T14:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/2c3144d40548ea23/iaso-bio-presented-comparative-clinical-outcomes-on-the-optimal-lymphodepletion-prior 2024-09-29T14:26:47+00:00 weekly 0.7 https://trial.medpath.com/news/7b6c8831db25f1b3/weekend-icymi-september-23-to-september-27-drug-topics 2024-09-29T14:24:42+00:00 weekly 0.7 https://trial.medpath.com/news/e30082e79d27a3f9/lumos-pharma-a-strong-buy-on-innovative-drug-prospects-and-solid-financials 2024-09-29T13:53:59+00:00 weekly 0.7 https://trial.medpath.com/news/c69ab5170033a73b/avicenna-ai-receives-fda-510-k-clearance-for-cervical-spine-fracture-ai-tool-healio 2024-09-29T13:51:13+00:00 weekly 0.7 https://trial.medpath.com/news/6526ba3a84379044/alnylam-highlights-new-data-from-helios-b-study-of-vutrisiran-for-the-treatment-of-quantisnow 2024-09-29T13:18:13+00:00 weekly 0.7 https://trial.medpath.com/news/e0bc0d5ffbbaf500/world-heart-day-2024-looking-back-at-cardiology-s-year-of-progress-in-cell-and-gene-therapy 2024-09-29T13:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/194c59c86f3a79a4/study-protocol-for-early-tracking-of-childhood-health-determinants-etched 2024-09-29T12:24:15+00:00 weekly 0.7 https://trial.medpath.com/news/3f7df16a3c5f743f/is-merck-stock-a-buy-the-globe-and-mail 2024-09-29T11:38:04+00:00 weekly 0.7 https://trial.medpath.com/news/09c2d5b5dc05bb15/858-therapeutics-drug-discovery-company-raises-50-million-series-b-pulse-2-0 2024-09-29T11:27:01+00:00 weekly 0.7 https://trial.medpath.com/news/79009cc3ffcd8099/effects-of-tenofovir-alafenamide-fumarate-on-serum-lipid-profiles-in-patients-with-chronic-hepatitis-b 2024-09-29T10:31:37+00:00 weekly 0.7 https://trial.medpath.com/news/edaaf1102b102120/2020-acr-guidelines-challenge-traditional-gout-management-in-chronic-kidney-disease-patients 2024-09-29T10:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/dbf6b5a89c005b3c/discussing-interim-findings-on-nemolizumab-for-atopic-dermatitis-with-diamant-thaci-md 2024-09-29T08:02:02+00:00 weekly 0.7 https://trial.medpath.com/news/32b4ab3dd20ec1d1/shingrix-vaccine-shows-strong-protection-against-shingles-in-ibd-patients-mayo-clinic-study-finds 2024-09-29T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8513f8d4e920e0ab/post-transplant-cyclophosphamide-breakthrough-expands-donor-pool-for-all-patients 2024-09-29T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8055a55c8d38b20e/delavirdine-gains-approval-as-second-nnrti-for-anti-hiv-combination-regimens-pubmed 2024-09-29T05:45:18+00:00 weekly 0.7 https://trial.medpath.com/news/f7655c4f8c11bb54/targeting-primary-tumor-metastasized-lesions-linked-to-improved-5-year-omhspc-survival 2024-09-29T05:24:16+00:00 weekly 0.7 https://trial.medpath.com/news/b5c8afca0167cb9f/ga-68-psma-11-tracer-could-guide-scintix-radiation-therapy-for-metastasized-prostate-cancer 2024-09-29T04:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/85e2ae75b3906933/abos-acumen-pharmaceuticals-inc-latest-stock-news-market-updates 2024-09-29T03:16:56+00:00 weekly 0.7 https://trial.medpath.com/news/6f5fbf42ed2f6a97/clinical-outcomes-of-patients-treated-with-ribociclib-in-combination-w-itt 2024-09-29T02:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/d0c95342fffd34b7/virologic-suppression-rate-and-associated-factors-for-third-line-hiv-treatment-in-addis-ababa 2024-09-29T00:37:58+00:00 weekly 0.7 https://trial.medpath.com/news/633b1905ec1e2f68/a-comparison-of-efficacy-of-erector-spinae-plane-block-versus-serratus-anterior-trials-journal 2024-09-28T23:37:50+00:00 weekly 0.7 https://trial.medpath.com/news/915a2791dea77d85/a-synuclein-antibody-lu-af82422-shows-disease-modifying-potential-in-phase-2-amulet 2024-09-28T22:56:04+00:00 weekly 0.7 https://trial.medpath.com/news/c9b4983ea183b035/isatuximab-lenalidomide-demonstrates-strong-efficacy-tolerability-in-smoldering-multiple-myeloma 2024-09-28T22:10:16+00:00 weekly 0.7 https://trial.medpath.com/news/e4c8fa367a40ab79/stress-confirmed-as-trigger-for-psoriasis-relapse-mcknight-s-long-term-care-news 2024-09-28T21:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/9f5202cc602d8f86/the-role-of-endovascular-therapy-for-stroke-patients-mcknight-s-long-term-care-news 2024-09-28T21:35:40+00:00 weekly 0.7 https://trial.medpath.com/news/59fb106ac9bd621d/study-protocol-for-a-cluster-randomized-controlled-community-effectiveness-trial-of-the 2024-09-28T21:31:34+00:00 weekly 0.7 https://trial.medpath.com/news/dd5f3f98950219f1/bgne-beigene-ltd-american-depositary-shares-latest-stock-news-market-updates 2024-09-28T21:18:45+00:00 weekly 0.7 https://trial.medpath.com/news/a070a017eff41a48/nurses-talk-aes-interstitial-lung-disease-before-treating-with-t-dxd 2024-09-28T21:00:12+00:00 weekly 0.7 https://trial.medpath.com/news/bb68511abd2c4f50/fda-clears-nvision-s-3d-printed-peek-interbody-system-voxelmatters 2024-09-28T20:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/ba412ab7f4ec7275/structural-basis-for-the-rescue-of-hyperexcitable-cells-by-the-amyotrophic-lateral-sclerosis 2024-09-28T19:58:01+00:00 weekly 0.7 https://trial.medpath.com/news/a14a09c9594febaf/omeicos-therapeutics-completes-enrollment-in-phase-2a-pmd-option-study-of-omt-28-in 2024-09-28T19:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/8ab73eb4a97fd673/patient-reported-outcomes-similar-between-adalimumab-admb-reference-product-in 2024-09-28T17:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/631b196e473253c5/today-s-health-roundup-schizophrenia-breakthrough-and-bird-flu-vaccination-pressures 2024-09-28T16:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/62d0af2dfc9a38e9/neurological-aes-not-significantly-affiliated-with-talquetamab-treatment-cancer-network 2024-09-28T16:55:50+00:00 weekly 0.7 https://trial.medpath.com/news/430cca0e7185c777/study-reveals-breakthrough-treatment-for-anxious-dogs-with-no-side-effects 2024-09-28T15:16:37+00:00 weekly 0.7 https://trial.medpath.com/news/e65576a85520693e/th17-cells-may-serve-as-biomarker-in-metastatic-melanoma-targeted-oncology 2024-09-28T15:02:12+00:00 weekly 0.7 https://trial.medpath.com/news/88eb9f981015d6a5/intervention-to-reduce-sedentary-behavior-among-desk-workers-did-not-lower-blood-pressure 2024-09-28T14:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/f66799c86f1768b4/new-intervention-to-protect-lungs-during-cardiac-surgery-feasible-safe-and-effective-study-finds 2024-09-28T14:31:32+00:00 weekly 0.7 https://trial.medpath.com/news/baaee49c38606b74/study-finds-estrogens-play-a-hidden-role-in-cancers-inhibiting-a-key-immune-cell 2024-09-28T14:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/c4f54c469b183afe/zydus-gets-usfda-approval-to-produce-its-generic-prostate-cancer-drug-company-news 2024-09-28T14:17:59+00:00 weekly 0.7 https://trial.medpath.com/news/a670ec2b8cfaa11b/naveris-to-showcase-advances-in-precision-surveillance-for-hpv-associated-morningstar 2024-09-28T13:42:45+00:00 weekly 0.7 https://trial.medpath.com/news/41e667d1f8cae2da/enliven-therapeutics-announces-positive-data-update-from-phase-1-clinical-trial-of-elvn 2024-09-28T13:40:42+00:00 weekly 0.7 https://trial.medpath.com/news/783bd292eeb209c8/taiwan-s-anbogen-inks-deal-with-beigene-to-evaluate-combination-therapy-in-colorectal-cancer 2024-09-28T13:06:30+00:00 weekly 0.7 https://trial.medpath.com/news/1596ee72877d6312/dea-calls-to-increase-production-of-psychedelics-for-clinical-research-lucid-news 2024-09-28T12:28:53+00:00 weekly 0.7 https://trial.medpath.com/news/36ae3efb2ff5811e/new-clinical-data-demonstrate-excellent-lesion-durability-with-pulseselecttm-pulsed-field 2024-09-28T11:00:47+00:00 weekly 0.7 https://trial.medpath.com/news/02f799dd574e2bb9/fda-approves-ge-healthcare-s-flurpiridaz-f-18-pet-radiotracer-for-cad 2024-09-28T10:10:43+00:00 weekly 0.7 https://trial.medpath.com/news/613fe46b9bcb2c51/enanta-s-phase-ii-challenge-data-position-a-second-potential-rsv-therapy-scrip 2024-09-28T09:39:36+00:00 weekly 0.7 https://trial.medpath.com/news/aa8b4cba6994df15/hypofractionated-radiation-therapy-improves-10-year-prostate-cancer-outcomes 2024-09-28T09:23:36+00:00 weekly 0.7 https://trial.medpath.com/news/5789459c58026979/the-weekly-roundup-september-23-27-dermatology-times 2024-09-28T09:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/09e8465bda5f6321/why-glp-1s-might-treat-a-plethora-of-conditions-becker-s-hospital-review 2024-09-28T08:34:30+00:00 weekly 0.7 https://trial.medpath.com/news/c9916e9b27080981/carvykti-r-is-the-first-and-only-cell-therapy-to-significantly-extend-overall-survival-versus 2024-09-28T08:30:34+00:00 weekly 0.7 https://trial.medpath.com/news/7f0724414a8d261a/johnson-johnson-cepheus-phase-3-study-shows-improvement-for-patients-with-multiple 2024-09-28T07:43:50+00:00 weekly 0.7 https://trial.medpath.com/news/19b8a927cd3572b0/deuruxolitinib-shows-efficacy-in-hair-regrowth-patient-satisfaction-and-psychosocial 2024-09-28T07:22:07+00:00 weekly 0.7 https://trial.medpath.com/news/acea5388bf051194/novel-antibody-drug-conjugate-hdp-101-shows-promise-in-relapsed-multiple-myeloma 2024-09-28T07:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/54584f2ff68a232c/radiation-therapy-the-immune-system-and-what-s-ahead-md-anderson-cancer-center 2024-09-28T07:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/248813578827ea9e/glucocorticoid-receptor-targeting-with-relacorilant-may-improve-ovarian-cancer-outcomes 2024-09-28T06:34:54+00:00 weekly 0.7 https://trial.medpath.com/news/187c38f40ddfd319/study-reveals-heightened-depression-risk-in-retinitis-pigmentosa-patients-particularly-among-young-adults 2024-09-28T06:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/750f2035211ca05b/pop-biotechnologies-announces-phase-3-trial-interim-results-published-for-covid-19 2024-09-28T06:09:54+00:00 weekly 0.7 https://trial.medpath.com/news/e84f341c66fed441/ultra-processed-foods-linked-to-17-higher-type-2-diabetes-risk-in-large-european-study 2024-09-28T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b9a4317f979996b2/zelenectide-pevedotin-shows-early-promise-as-less-toxic-alternative-to-standard 2024-09-28T05:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/8b4892cc4e6dc681/commonly-used-drug-could-transform-treatment-of-rare-muscle-disorder-medical-xpress 2024-09-28T05:04:29+00:00 weekly 0.7 https://trial.medpath.com/news/18244193d250e965/olomorasib-combo-elicits-favorable-efficacy-in-nsclc-targeted-oncology 2024-09-28T05:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/aacb483553fd71f6/abbvie-submits-biologics-license-application-to-the-fda-for-telisotuzumab-vedotin-teliso 2024-09-28T04:17:25+00:00 weekly 0.7 https://trial.medpath.com/news/984b6bf8249750c7/dietary-factors-show-protective-effects-against-iga-nephropathy-in-landmark-mendelian-study 2024-09-28T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dac55d1f85d9ffd3/vitamin-d-for-the-management-of-chronic-obstructive-pulmonary-disease-pubmed 2024-09-28T02:43:51+00:00 weekly 0.7 https://trial.medpath.com/news/2f0e4e6e4e39764d/dr-victoria-kunene-on-personalised-colorectal-cancer-vaccines-for-prevention-and-therapy 2024-09-28T02:03:51+00:00 weekly 0.7 https://trial.medpath.com/news/c15f29173ed286dc/here-s-the-article-based-on-the-provided-information-by-investing-com 2024-09-28T01:48:40+00:00 weekly 0.7 https://trial.medpath.com/news/eaceb10615b14d2d/effectiveness-of-the-dyadic-coping-intervention-of-social-participation-dcisp-for-stroke-survivors 2024-09-28T01:39:20+00:00 weekly 0.7 https://trial.medpath.com/news/b953298294263cd8/wall-street-swot-aquestive-therapeutics-stock-poised-for-potential-breakthrough 2024-09-28T00:49:17+00:00 weekly 0.7 https://trial.medpath.com/news/6fea78f425f042eb/cepheus-outcomes-support-daratumumab-plus-vrd-as-soc-in-multiple-myeloma 2024-09-28T00:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/ad8317c53d9af9ad/fda-grants-ind-clearance-for-minovia-s-phase-ib-mds-therapy-trial 2024-09-27T23:08:19+00:00 weekly 0.7 https://trial.medpath.com/news/d4097cc77b6fd724/dr-gluz-on-survival-outcomes-with-de-escalated-neoadjuvant-regimens-in-hr-her2 2024-09-27T22:53:04+00:00 weekly 0.7 https://trial.medpath.com/news/7e4da9e68e80c8f1/abbvie-s-parkinson-s-drug-tavapadon-a-market-perform-rating-amidst-competitive 2024-09-27T22:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/7339c482f9a27f76/late-breaking-data-at-eadv-of-esk-001-an-oral-tyk2-inhibitor-for-the-treatment-of-biospace 2024-09-27T22:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/7978ed3735275be3/fda-grants-expanded-indication-for-linear-health-sciences-orchid-safety-release-valve 2024-09-27T20:42:13+00:00 weekly 0.7 https://trial.medpath.com/news/32d2dbe62688868d/has-albrecht-been-undone-insights-holland-knight 2024-09-27T20:37:39+00:00 weekly 0.7 https://trial.medpath.com/news/02bb18e573e8bde5/fda-approves-selpercatinib-for-ret-fusion-medullary-thyroid-cancer 2024-09-27T19:37:47+00:00 weekly 0.7 https://trial.medpath.com/news/f2efa8cdd7c91901/boston-scientific-wins-farapulse-pfa-approval-in-japan-massdevice 2024-09-27T19:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/2386495bf230db17/cereno-scientific-announces-positive-topline-results-of-phase-iia-trial-with-lead-candidate 2024-09-27T18:42:30+00:00 weekly 0.7 https://trial.medpath.com/news/e97e826473a1412e/neurona-therapeutics-announces-participation-in-upcoming-investor-conferences-in-october 2024-09-27T18:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/ba2e3bdd782c0363/lexicon-to-present-phase-3-trial-design-for-sotagliflozin-globenewswire 2024-09-27T18:10:16+00:00 weekly 0.7 https://trial.medpath.com/news/ad0d917eb0ecd664/grand-rounds-october-18-2024-rigorous-testing-of-behavior-change-interventions 2024-09-27T18:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/7e824634a4eb1ce2/staggering-breast-cancer-breakthrough-as-drug-trial-drastically-shrinks-tumours-by-65-uk 2024-09-27T18:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/bef27d607853445f/antibody-drug-conjugates-and-immune-checkpoint-inhibitors-in-cancer-treatment-nature 2024-09-27T17:28:28+00:00 weekly 0.7 https://trial.medpath.com/news/a959f928275c3a46/wall-street-swot-atyr-pharma-stock-rides-wave-of-clinical-progress-amid-risks 2024-09-27T17:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/73c4f373f49952f7/galectin-9-as-a-new-biomarker-of-acute-on-chronic-liver-failure-scientific-reports-nature 2024-09-27T16:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/5e367d7bdeff2845/biosimilars-generate-12-3-billion-in-healthcare-savings-for-2023-yet-market-challenges-persist 2024-09-27T16:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/129aa6439afb0e2c/pas-004-has-tolerable-safety-profile-and-preliminary-efficacy-in-mapk-driven-solid-tumors 2024-09-27T15:59:49+00:00 weekly 0.7 https://trial.medpath.com/news/2eb815c2d683bb01/in-first-type-1-diabetic-cured-by-allogeneic-stem-cell-transplant 2024-09-27T15:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/2b5d9768a0307d3a/nyu-langone-health-in-the-news-friday-september-27-2024 2024-09-27T15:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/291c0d9f0305cc1e/lundbeck-presents-results-from-two-studies-in-multiple-system-atrophy-at-international 2024-09-27T15:20:28+00:00 weekly 0.7 https://trial.medpath.com/news/828e459ed11a8aa3/rezolute-stock-holds-steady-with-buy-rating-from-hc-wainwright-investing-com 2024-09-27T15:13:07+00:00 weekly 0.7 https://trial.medpath.com/news/c4e40c2bb205eb6a/key-considerations-for-digital-decentralised-clinical-trials-from-a-feasibility-study-assessing 2024-09-27T15:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/3e65dee682065b56/non-clinical-evaluation-of-pmil12-gene-therapy-for-approval-of-the-phase-i-clinical-study 2024-09-27T15:08:45+00:00 weekly 0.7 https://trial.medpath.com/news/1190c3eb9c7fba0c/j-j-builds-case-for-talvey-fda-panel-questions-pd-1-drugs-for-certain-cancers 2024-09-27T14:58:06+00:00 weekly 0.7 https://trial.medpath.com/news/163e8d43be9da900/the-data-are-clear-patients-regain-weight-after-stopping-glp-1-drugs-medpage-today 2024-09-27T14:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/1a78d42ad4d5f33d/practical-lessons-and-insights-from-seasoned-drug-hunters 2024-09-27T14:19:46+00:00 weekly 0.7 https://trial.medpath.com/news/0ab06099955f8364/bristol-myers-squibb-shares-move-higher-on-fda-approval-of-schizophrenia-drug 2024-09-27T13:41:01+00:00 weekly 0.7 https://trial.medpath.com/news/f34c23e218974660/leo-pharma-files-for-approval-of-psoriasis-treatment-enstilar-in-china-medwatch 2024-09-27T13:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/bec46c1a6bf5646b/nccn-guidelines-update-evolving-treatment-landscape-for-graft-vs-host-disease-management 2024-09-27T13:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/1a9430f10d63fc5d/a-bayesian-multivariate-hierarchical-model-for-developing-a-treatment-benefit-index-using 2024-09-27T12:51:47+00:00 weekly 0.7 https://trial.medpath.com/news/eaa31507c826e0e6/septerna-announces-initiation-of-phase-1-clinical-trial-with-sep-786-a-novel-oral-small 2024-09-27T12:47:32+00:00 weekly 0.7 https://trial.medpath.com/news/ea14e4b3c4a246ac/bayer-s-bemdaneprocel-for-parkinson-s-disease-shows-positive-data-at-24-months 2024-09-27T12:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/b8d8a0da256adca4/savara-announces-expanded-access-program-eap-for-molgramostim-inhalation-solution 2024-09-27T12:16:32+00:00 weekly 0.7 https://trial.medpath.com/news/b1cba7c2777168f9/pfizer-jefferies-lowers-price-target-marketscreener 2024-09-27T12:16:10+00:00 weekly 0.7 https://trial.medpath.com/news/799d993e97caabbb/cardurion-pharmaceuticals-selected-as-an-endpoints-11-most-promising-biotech-company 2024-09-27T12:12:38+00:00 weekly 0.7 https://trial.medpath.com/news/855bff9163034dbb/impact-biotech-announces-50-enrollment-in-phase-3-enlighted-clinical-trial-of 2024-09-27T12:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/f868d28019b07e55/real-world-performance-analysis-of-gprc5d-bispecific-therapies-in-relapsed-multiple-myeloma 2024-09-27T11:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/5e007b659922a22d/mhra-approves-first-medicine-for-rare-immune-disease-apds-gov-uk 2024-09-27T11:37:56+00:00 weekly 0.7 https://trial.medpath.com/news/37110d2dad687abf/reporting-and-communication-of-sample-size-calculations-in-adaptive-clinical-trials 2024-09-27T11:37:42+00:00 weekly 0.7 https://trial.medpath.com/news/7d9cd4c4c1e16e01/stem-cells-reverse-woman-s-diabetes-a-world-first-healthleaders-media 2024-09-27T11:25:43+00:00 weekly 0.7 https://trial.medpath.com/news/c469127e7ca4159a/press-release-dupixent-approved-in-china-as-the-first-ever-biologic-medicine-for-patients 2024-09-27T11:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/3f43225e61ac573b/poltreg-begins-car-treg-development-for-neuroinflammatory-disease 2024-09-27T11:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/673f2561e24b70ae/occlusive-retinal-vasculitis-associated-with-intravitreal-faricimab-injections 2024-09-27T10:41:22+00:00 weekly 0.7 https://trial.medpath.com/news/d5c46582557788d6/alembic-pharma-secures-fda-approval-for-schizophrenia-treatment-stocks-in-red 2024-09-27T10:26:29+00:00 weekly 0.7 https://trial.medpath.com/news/afc8f0b1b53fbfe7/ose-immunotherapeutics-announces-historic-h1-2024-results-and-provides-corporate-update 2024-09-27T09:45:47+00:00 weekly 0.7 https://trial.medpath.com/news/c48c4082b7ffa5f3/a-multi-center-double-blind-placebo-controlled-randomized-parallel-group-non-inferiority 2024-09-27T09:39:56+00:00 weekly 0.7 https://trial.medpath.com/news/0c1766c50b0f30c6/trial-of-pathogen-reduced-cryoprecipitate-vs-cryoprecipitated-ahf-to-lower-operative 2024-09-27T09:39:56+00:00 weekly 0.7 https://trial.medpath.com/news/e02ddc1841f50885/upping-dose-of-anti-opioid-drug-might-work-better-to-curb-addiction 2024-09-27T09:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/9e5a62eec3cf776c/viral-infections-emerge-as-critical-consideration-in-rheumatic-disease-management 2024-09-27T08:42:53+00:00 weekly 0.7 https://trial.medpath.com/news/714d4a3976749d53/dispute-over-duchenne-gene-therapy-highlights-thorny-access-issues-stat-news 2024-09-27T08:35:38+00:00 weekly 0.7 https://trial.medpath.com/news/23f05e5bfbecabf6/urteste-expands-development-of-innovative-diagnostic-projects-biospace 2024-09-27T08:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/7f89a8a9ac973c31/genprex-makes-moves-to-bring-its-gene-therapy-product-reqorsa-to-mesothelioma 2024-09-27T08:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/45eaafb505f29878/formycon-and-fresenius-kabi-receive-european-commission-approval-for-fyb202-otulfi 2024-09-27T07:24:52+00:00 weekly 0.7 https://trial.medpath.com/news/8956fe3a8edd7331/xbrane-provides-update-from-scientific-advice-with-us-fda-on-xdivanetm-opdivo 2024-09-27T07:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/6cc13ff30be754ab/psma-targeted-radiopharmaceuticals-transform-advanced-prostate-cancer-treatment-landscape 2024-09-27T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a30bc6a7dc5064fc/shionogi-submits-new-drug-application-in-japan-for-zuranolone-as-a-treatment-for-major 2024-09-27T02:35:10+00:00 weekly 0.7 https://trial.medpath.com/news/0ea07f906a0e8223/pilot-study-of-il-1-antagonist-anakinra-for-treatment-of-endometriosis-dove-medical-press 2024-09-27T02:27:10+00:00 weekly 0.7 https://trial.medpath.com/news/973cdf8a4f13c0c4/travere-therapeutics-announces-voluntary-pause-of-enrollment-in-the-phase-3-harmony 2024-09-27T02:13:08+00:00 weekly 0.7 https://trial.medpath.com/news/f39db35848db5361/arpa-h-awards-27m-to-phare-bio-for-ai-powered-antibiotic-discovery-platform 2024-09-27T02:12:39+00:00 weekly 0.7 https://trial.medpath.com/news/038ef196454e5647/union-plans-phase-iii-trial-for-atopic-dermatitis-after-phase-iib-win-clinical-trials-arena 2024-09-27T01:25:36+00:00 weekly 0.7 https://trial.medpath.com/news/05248eb11d6964d1/biocon-partners-with-tabuk-to-launch-glp-1-therapies-across-middle-east-markets 2024-09-27T00:16:42+00:00 weekly 0.7 https://trial.medpath.com/news/1ce6696e311cb102/surufatinib-plus-toripalimab-combined-with-etoposide-and-cisplatin-as-first-line-treatment-in-nature 2024-09-27T00:10:29+00:00 weekly 0.7 https://trial.medpath.com/news/f7f1047c8febc3b7/abbvie-submits-biologics-license-application-to-the-fda-for-telisotuzumab-vedotin-teliso-v-in-previously-treated-non-small-cell-lung-cancer 2024-09-27T00:09:06+00:00 weekly 0.7 https://trial.medpath.com/news/433cb2907cb13421/canadian-real-world-study-finds-no-increased-infection-risk-with-tnf-inhibitor-biosimilars 2024-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/706c6d1cdcb0da6b/new-published-data-show-reproducibility-and-utility-of-perspectum-s-mri-in-patients-with 2024-09-26T23:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/5492ff7743c9054e/cassava-sciences-shares-fall-after-sec-charges-for-misleading-alzheimer-s-drug-trial-claims 2024-09-26T23:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/45de8b3f992559d9/bristol-myers-squibb-and-2seventy-bio-halt-karmma-9-trial-in-patients-with-newly 2024-09-26T21:11:45+00:00 weekly 0.7 https://trial.medpath.com/news/cfdc175b3463b875/establishment-labs-receives-u-s-fda-approval-for-motiva-implants-yahoo-finance 2024-09-26T21:09:43+00:00 weekly 0.7 https://trial.medpath.com/news/32e81d67b883502a/intrapatient-intermetastatic-heterogeneity-determined-by-triple-tracer-pet-imaging-in 2024-09-26T20:47:15+00:00 weekly 0.7 https://trial.medpath.com/news/996d267195bc8b3a/vivani-can-begin-first-in-human-glp-1-implant-trial-in-australia-drug-delivery-business 2024-09-26T19:59:55+00:00 weekly 0.7 https://trial.medpath.com/news/516109a7b4f1310d/belantamab-combo-shows-promising-outcomes-in-transplant-eligible-ndmm 2024-09-26T19:49:41+00:00 weekly 0.7 https://trial.medpath.com/news/ba90459c7213a218/orion-s-collaboration-partner-bayer-submits-application-to-u-s-fda-for-third-indication-of 2024-09-26T19:33:57+00:00 weekly 0.7 https://trial.medpath.com/news/8c37dac02ba8bca7/enanta-pharmaceuticals-announces-positive-topline-results-for-edp-323-in-a-phase-biospace 2024-09-26T19:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/165ae44a66c83e91/cyclacel-pharmaceuticals-announces-completion-of-enrollment-in-the-biomarker-enriched 2024-09-26T19:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/3defb0bd00471b53/israeli-device-is-new-drug-free-solution-for-men-coping-with-ed-nocamels 2024-09-26T19:28:11+00:00 weekly 0.7 https://trial.medpath.com/news/72db4b83c282bdbc/placebos-linked-to-potential-harms-in-ibd-clinical-trials-medpage-today 2024-09-26T19:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/6e4e79a117314ff7/genentech-s-gazyva-hits-primary-endpoint-in-late-stage-kidney-disease-trial 2024-09-26T18:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/6c04fcacf521a808/fda-lifts-clinical-hold-on-bmf-219-in-type-2-and-type-1-diabetes-trials-morningstar 2024-09-26T18:35:33+00:00 weekly 0.7 https://trial.medpath.com/news/31d4b72ca59dc239/based-on-hope-and-love-ub-celebrates-opening-of-foxg1-research-center-ubnow 2024-09-26T18:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/6337fcd1102d1ef4/thrombolytic-science-receives-fda-investigational-new-drug-clearance 2024-09-26T18:02:08+00:00 weekly 0.7 https://trial.medpath.com/news/ba46090e64fafc3c/journalists-question-safety-and-effectiveness-of-new-alzheimer-s-drug 2024-09-26T17:49:27+00:00 weekly 0.7 https://trial.medpath.com/news/c2c126529db7b953/patient-friendly-news-you-can-use-september-creakyjoints 2024-09-26T17:35:34+00:00 weekly 0.7 https://trial.medpath.com/news/41a073590b9f64b8/eye-on-pharma-ec-approved-ustekinumab-zymfentra-expansion-biosimilar-policy-briefing 2024-09-26T17:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/a7b9387911c4857c/eyenovia-announces-launch-and-commercial-availability-of-clobetasol-propionate-quantisnow 2024-09-26T17:21:56+00:00 weekly 0.7 https://trial.medpath.com/news/d3edc608ce9f61d7/polarcool-takes-an-important-step-towards-launching-in-the-us-cision-news 2024-09-26T16:50:56+00:00 weekly 0.7 https://trial.medpath.com/news/2f1b0574be1a3a53/biomedical-research-improvements-needed-to-the-quality-of-information-about-dod-and 2024-09-26T16:49:04+00:00 weekly 0.7 https://trial.medpath.com/news/b168deef48c3f64e/her2-and-lung-cancer-new-test-holds-great-promise-to-help-far-more-patients 2024-09-26T16:36:53+00:00 weekly 0.7 https://trial.medpath.com/news/78e8ddbc657c7eb2/intrathecal-pain-pump-improves-pancreatic-cancer-patient-s-life 2024-09-26T16:36:16+00:00 weekly 0.7 https://trial.medpath.com/news/2ff1404ead096939/new-self-swab-hpv-test-is-an-alternative-to-pap-smears-here-s-how-it-works-live-science 2024-09-26T16:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/1918fb338c5b7757/axonics-wins-regulatory-nod-in-australia-for-latest-sacral-neuromod-system-massdevice 2024-09-26T16:01:47+00:00 weekly 0.7 https://trial.medpath.com/news/5a13e7a4058da472/moderna-blamed-after-children-offered-ps1500-to-take-part-in-covid-19-trial 2024-09-26T15:58:40+00:00 weekly 0.7 https://trial.medpath.com/news/62f4e9df8b103b6c/nih-plots-path-forward-for-clinical-trials-of-long-covid-treatments-c-en 2024-09-26T15:50:34+00:00 weekly 0.7 https://trial.medpath.com/news/5462a29142223fd4/abbvie-announces-positive-topline-results-from-phase-3-tempo-1-trial-evaluating 2024-09-26T15:38:07+00:00 weekly 0.7 https://trial.medpath.com/news/a72828c6d8e34ecc/pfizer-withdraws-scd-drug-oxbryta-after-ema-discloses-16-deaths-in-trials 2024-09-26T15:37:35+00:00 weekly 0.7 https://trial.medpath.com/news/ea9af2d7a5ce6638/fda-proposes-reclassifying-hepatitis-b-assays-medtech-dive 2024-09-26T15:20:15+00:00 weekly 0.7 https://trial.medpath.com/news/5359b9e9b8b51740/press-releases-wednesday-sep-25-2024-genentech 2024-09-26T15:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/2f9c312894ae115a/immunai-astrazeneca-collaborate-to-optimize-cancer-clinical-trials-the-jerusalem-post 2024-09-26T15:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/4dcb3edd5e94b6de/kidney-cancer-questions-answered-from-protein-intake-to-clinical-trials-cure-today 2024-09-26T15:05:31+00:00 weekly 0.7 https://trial.medpath.com/news/e0205c41059efa80/breast-cancer-drugs-fda-approval-development-time-efficacy-clinical-benefits-innovation 2024-09-26T14:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/b0a0704849a96dd5/phase-3-lunar-trial-dr-rolfo-discusses-new-analysis-at-iaslc-2024-world-conference 2024-09-26T14:43:12+00:00 weekly 0.7 https://trial.medpath.com/news/aba7634f74646e86/govt-drafts-sop-to-regulate-clinical-research-organizations-mint 2024-09-26T14:40:16+00:00 weekly 0.7 https://trial.medpath.com/news/1c5e767ac9ca16c2/alzheimer-s-breakthrough-as-wonder-drug-approved-but-might-not-be-available-in-the-uk 2024-09-26T14:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/97e224a169b4814c/rx-road-map-glofitamab-gxbm-columvi-oncology-nursing-news 2024-09-26T14:10:04+00:00 weekly 0.7 https://trial.medpath.com/news/0ba2834e40aec12e/eadv-2024-wegovy-shows-promise-in-treating-common-chronic-skin-condition 2024-09-26T13:42:45+00:00 weekly 0.7 https://trial.medpath.com/news/13bf987e68a5d43e/a-first-in-human-study-of-cinrebafusp-alfa-a-her2-4-1bb-bispecific-molecule-in-patients 2024-09-26T13:28:32+00:00 weekly 0.7 https://trial.medpath.com/news/4d125d9eb21ff5ab/acasti-pharma-shares-maintain-buy-rating-from-hc-wainwright-investing-com 2024-09-26T13:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/13b78c833f598a59/longeveron-to-attend-alliance-for-regenerative-medicine-s-cell-gene-meeting-on-the-mesa 2024-09-26T13:11:27+00:00 weekly 0.7 https://trial.medpath.com/news/ec0462b41b0d1caa/metabolic-reprogramming-of-t-cells-may-enhance-checkpoint-inhibitor-therapy-newsroom 2024-09-26T13:10:23+00:00 weekly 0.7 https://trial.medpath.com/news/61153c3feef10992/mural-oncology-s-first-virtual-investor-day-to-highlight-late-stage-clinical-progress 2024-09-26T12:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/af88b11dd98d17c1/cervomed-to-deliver-late-breaking-oral-presentations-at-the-17th-clinical-trials-on 2024-09-26T12:32:21+00:00 weekly 0.7 https://trial.medpath.com/news/419c165c441bdf3b/fda-grants-fast-track-designation-to-ptc518-huntington-s-disease-program-stock-titan 2024-09-26T12:17:27+00:00 weekly 0.7 https://trial.medpath.com/news/fbabd478090d13fd/projenx-and-unlearn-announce-partnership-to-augment-als-clinical-trial-pro-101-with 2024-09-26T12:00:29+00:00 weekly 0.7 https://trial.medpath.com/news/7f25108367cf2d07/vertex-highlights-first-oral-presentation-of-phase-3-clinical-data-of-the-vanza-triple-and 2024-09-26T11:34:32+00:00 weekly 0.7 https://trial.medpath.com/news/7ee29d7f68c280f7/dong-a-st-s-ecg-monitoring-platform-hicardi-h100-receives-u-s-fda-approval 2024-09-26T11:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/c69f33428d28e07e/ani-pharmaceuticals-announces-fda-approval-launch-of-ketoconazole-shampoo-2 2024-09-26T10:57:11+00:00 weekly 0.7 https://trial.medpath.com/news/cac777e9d98e17cb/hamlet-biopharma-reports-positive-results-from-phase-ii-study-in-acute-cystitis 2024-09-26T10:38:10+00:00 weekly 0.7 https://trial.medpath.com/news/8e79d7be38ff4d49/novel-monoclonal-antibody-shows-promise-in-ulcerative-colitis-medpage-today 2024-09-26T10:35:13+00:00 weekly 0.7 https://trial.medpath.com/news/ea4e266519ca1dfb/during-ny-climate-week-alex-zhavoronkov-phd-eurekalert 2024-09-26T10:21:53+00:00 weekly 0.7 https://trial.medpath.com/news/4e20b98cf02d77f4/innovent-announces-nmpa-acceptance-of-nda-for-picankibart-anti-il-23p19-antibody-for 2024-09-26T10:15:54+00:00 weekly 0.7 https://trial.medpath.com/news/4ca96530d5108d31/finance-to-pharma-q-a-with-renee-aguiar-lucander-pharmaceutical-executive 2024-09-26T10:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/6f5475e7ff8de19f/inbiome-receives-fda-breakthrough-device-designation-for-revolutionary-molecular 2024-09-26T09:46:17+00:00 weekly 0.7 https://trial.medpath.com/news/f2b865ef35f58a71/amgn-a-stock-on-the-move-that-s-blessed-with-a-promising-drug-pipeline-moneyshow 2024-09-26T09:37:42+00:00 weekly 0.7 https://trial.medpath.com/news/e3d44444235eb9b7/trial-confirms-life-changing-impact-of-gene-therapy-for-hemophilia-b 2024-09-26T09:37:31+00:00 weekly 0.7 https://trial.medpath.com/news/acc345d1c13586d0/breakthrough-therapy-designation-btd-for-biocity-s-sc0062-a-selective-endothelin-type 2024-09-26T09:20:10+00:00 weekly 0.7 https://trial.medpath.com/news/07759d8d62a9f954/1st-pediatric-insomnia-drug-launched-in-korea-pharma-article-kbr 2024-09-26T08:44:51+00:00 weekly 0.7 https://trial.medpath.com/news/edec2ece09b2fd4d/cuh-plays-key-role-in-international-cancer-studies-cambridge-university-hospitals 2024-09-26T08:35:54+00:00 weekly 0.7 https://trial.medpath.com/news/4bd702597e457a2b/obesity-drug-developer-bioage-raises-198m-in-ipo-pharmaphorum 2024-09-26T08:04:35+00:00 weekly 0.7 https://trial.medpath.com/news/4e8bae44fb902f8d/arthex-biotech-announces-participation-in-8th-annual-chardan-genetic-medicines-conference 2024-09-26T08:04:24+00:00 weekly 0.7 https://trial.medpath.com/news/08d89dc79b39c9c5/cabaletta-bio-to-present-new-and-updated-clinical-data-on-caba-201-in-oral-and-poster 2024-09-26T07:57:05+00:00 weekly 0.7 https://trial.medpath.com/news/3a1917cd337d679d/renovorx-increases-production-of-fda-cleared-renovocath-r-delivery-system-in-biospace 2024-09-26T07:45:02+00:00 weekly 0.7 https://trial.medpath.com/news/19f5dae0dd9a11e7/who-issues-new-guidance-to-enhance-clinical-trials-worldwide-news-medical 2024-09-26T07:33:08+00:00 weekly 0.7 https://trial.medpath.com/news/fb354934b1b8fad7/pfizer-pulls-sickle-cell-treatment-over-deadly-complication-risks-geneonline-news 2024-09-26T07:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/dfbac4f9706c1456/synairgen-making-substantial-progress-towards-phase-ii-trial-aim-sng-otc-syggf 2024-09-26T07:08:33+00:00 weekly 0.7 https://trial.medpath.com/news/8538f02d2e973d5e/elixirgen-therapeutics-receives-rare-pediatric-disease-designation-for-exg-34217-in-biospace 2024-09-26T07:03:28+00:00 weekly 0.7 https://trial.medpath.com/news/530aab628a2aa2d6/cidara-therapeutics-announces-two-presentations-on-innovative-drug-fc-conjugate 2024-09-26T06:16:56+00:00 weekly 0.7 https://trial.medpath.com/news/84cee342feec149f/palisade-bio-provides-update-on-progress-toward-launch-of-phase-1-human-clinical-biospace 2024-09-26T06:16:55+00:00 weekly 0.7 https://trial.medpath.com/news/6e2fea9981ae10c1/personalized-medicine-and-genetic-markers-drive-major-advances-in-pediatric-cancer-treatment 2024-09-26T06:00:53+00:00 weekly 0.7 https://trial.medpath.com/news/dc591e5ba7b16689/cellbion-eyes-global-expansion-in-radiopharmaceuticals-after-kosdaq-ipo-kbr 2024-09-26T05:47:50+00:00 weekly 0.7 https://trial.medpath.com/news/665e048e7f562971/mirai-bio-launches-50m-ai-platform-to-accelerate-genetic-medicine-development 2024-09-26T05:21:30+00:00 weekly 0.7 https://trial.medpath.com/news/5e93ab1d38173b3b/a-two-pronged-attack-on-ovarian-cancer-hmri 2024-09-26T05:02:01+00:00 weekly 0.7 https://trial.medpath.com/news/903dda0d49d209ee/breakthrough-treatment-for-recurrent-pregnancy-loss-mirage-news 2024-09-26T04:11:13+00:00 weekly 0.7 https://trial.medpath.com/news/a8d954b863383517/post-stroke-fever-prevention-still-lacking-in-clinical-benefit-medpage-today 2024-09-26T03:42:31+00:00 weekly 0.7 https://trial.medpath.com/news/5848650c4ffcaf45/glp-1-agonists-poised-to-impact-breast-cancer-care-targeted-oncology 2024-09-26T03:04:47+00:00 weekly 0.7 https://trial.medpath.com/news/7880ebf2ce459716/uk-labour-government-s-nhs-reform-ai-and-technology-at-forefront-of-10-year-healthcare-transformation-plan 2024-09-26T02:30:03+00:00 weekly 0.7 https://trial.medpath.com/news/cb588b7632ba3c86/daehwa-pharm-s-liporaxel-wins-chinese-approval-to-treat-gastric-cancer-pharma-article-kbr 2024-09-26T02:29:38+00:00 weekly 0.7 https://trial.medpath.com/news/7d07dcad01ff177d/synergy-spine-solutions-announces-completion-of-patient-enrollment-in-the-synergy-disc 2024-09-26T02:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/bf32818b0c1b7bc6/medidata-streamlines-clinical-trial-compensation-with-new-patient-payments-platform 2024-09-26T00:38:03+00:00 weekly 0.7 https://trial.medpath.com/news/abd9837221db6b07/entera-bio-and-opko-health-provide-update-on-pk-pd-results-of-oral-oxyntomodulin-glp 2024-09-26T00:30:02+00:00 weekly 0.7 https://trial.medpath.com/news/f608fd4aa70883c2/discovery-of-tyra-300-first-oral-selective-fgfr3 2024-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6ec66246fc39741f/sanofi-sees-promise-in-cd73-apexonco-clinical-trials-news-and-analysis 2024-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/628c5bebec4cf923/anixa-announces-plans-to-launch-phase-ii-breast-cancer-vaccine-trial 2024-09-25T23:21:10+00:00 weekly 0.7 https://trial.medpath.com/news/218cd228e0911e29/yourchoice-doses-participants-in-trial-of-birth-control-pill-for-men 2024-09-25T23:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/7e4486a63bf8d41d/biomarker-data-from-oncology-trial-for-adicet-bio-s-game-delta-t-cell-therapy-adi-001 2024-09-25T23:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/2d202168e4826b4d/new-analysis-demonstrates-the-efficacy-of-rinvoq-r-upadacitinib-in-atopic-dermatitis 2024-09-25T23:04:45+00:00 weekly 0.7 https://trial.medpath.com/news/415b609a832848c8/alzheimer-s-drug-faces-scrutiny-over-safety-efficacy-concerns-neuroscience-news 2024-09-25T22:56:09+00:00 weekly 0.7 https://trial.medpath.com/news/d239b21fed28dfef/sam-neill-credits-breakthrough-cancer-treatment-for-saving-his-life-easterneye 2024-09-25T22:41:05+00:00 weekly 0.7 https://trial.medpath.com/news/a49397601e003605/uthealth-houston-s-minimally-invasive-treatment-newswise 2024-09-25T22:28:29+00:00 weekly 0.7 https://trial.medpath.com/news/a3d2f153120b2417/struggling-2seventy-scraps-a-key-cancer-study-biopharma-dive 2024-09-25T21:52:25+00:00 weekly 0.7 https://trial.medpath.com/news/6e8a9ece87758966/novel-antiviral-appears-effective-for-severe-rsv-in-infants-toddlers-medpage-today 2024-09-25T21:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/1a85afe04805a114/fda-approved-topical-ruxolitinib-and-the-evolving-treatment-paradigm-dermatology-times 2024-09-25T21:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/6c81fe1d6a966f95/type-2-diabetes-study-the-reporter-uab 2024-09-25T21:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/a26d8552c14a102b/pola-r-chp-or-r-choep-for-first-line-therapy-of-younger-patients-with-high-risk-diffuse-large 2024-09-25T20:37:58+00:00 weekly 0.7 https://trial.medpath.com/news/5d7cb736727e972c/peaky-blinders-star-says-he-would-be-dead-if-not-for-experimental-drug 2024-09-25T20:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/6c8807f766dc7d84/unc-fast-tracks-personalized-treatment-for-twins-with-ultra-rare-genetic-disorder 2024-09-25T20:31:59+00:00 weekly 0.7 https://trial.medpath.com/news/cfbfc9747b6f8942/experts-share-intriguing-early-phase-sarcoma-studies-from-the-2024-esmo-congress 2024-09-25T20:23:59+00:00 weekly 0.7 https://trial.medpath.com/news/651840107e33ef96/duke-street-bio-granted-approval-by-european-medicines-agency-to-launch-next 2024-09-25T20:23:55+00:00 weekly 0.7 https://trial.medpath.com/news/42972219167cbade/fda-approves-tagrisso-for-some-with-advanced-nsclc-cure-today 2024-09-25T20:22:16+00:00 weekly 0.7 https://trial.medpath.com/news/6aed2cba630afdd4/inventiva-provides-a-corporate-update-and-reports-its-unaudited-2024-first-half-financial-results 2024-09-25T20:15:32+00:00 weekly 0.7 https://trial.medpath.com/news/7ba8600102c1602d/immunization-roundup-fda-approves-flumist-updated-novavax-covid-19-vaccine 2024-09-25T19:47:16+00:00 weekly 0.7 https://trial.medpath.com/news/d8d75b87a2fe6ba3/ema-to-discuss-pfizer-s-sickle-cell-drug-oxbryta-after-patient-deaths-endpoints-news 2024-09-25T19:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/b6323a9d7dbb0b7a/clinicaltrials-eu-platform-rolled-out-across-europe 2024-09-25T19:15:04+00:00 weekly 0.7 https://trial.medpath.com/news/d04123c016155f34/mesopher-cell-therapy-increases-2-year-rfs-rate-in-resected-pancreatic-cancer-by-50 2024-09-25T18:31:15+00:00 weekly 0.7 https://trial.medpath.com/news/725e8ce7c5484f03/tcbp-announces-site-opening-of-guys-and-st-thomas-hospital-pr-newswire 2024-09-25T18:30:37+00:00 weekly 0.7 https://trial.medpath.com/news/bf8bafd13b1ec6de/non-operative-management-of-rectal-cancer-does-not-worsen-distant-rfs 2024-09-25T18:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/27be34923c735bd5/galmed-publishes-results-from-aramchol-phase-3-open-label-part-in-hepatology-pr-newswire 2024-09-25T18:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/f600e63cd26aa1ec/semaglutide-may-reduce-opioid-overdoses-a-new-study-suggests-science-news 2024-09-25T17:59:18+00:00 weekly 0.7 https://trial.medpath.com/news/8230351bfd2956da/baptist-health-treats-first-liver-cancer-patients-with-histotripsy 2024-09-25T17:57:12+00:00 weekly 0.7 https://trial.medpath.com/news/ce0508b9ca32b401/acasti-announces-completion-of-patient-enrollment-in-globenewswire 2024-09-25T17:30:40+00:00 weekly 0.7 https://trial.medpath.com/news/cc31fcf2125353ff/promising-drug-combo-targets-aggressive-bladder-cancers-medical-xpress 2024-09-25T17:21:49+00:00 weekly 0.7 https://trial.medpath.com/news/0ec9cd155a2222f9/ayuvis-incubated-at-hsc-receives-fda-fast-track-for-drug-preventing-preterm-infant-lung-disease 2024-09-25T17:13:56+00:00 weekly 0.7 https://trial.medpath.com/news/b35744716d155624/uplizna-improved-outcomes-over-placebo-in-phase-3-trials-for-igg4-rd-myasthenia-gravis 2024-09-25T16:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/3c255b94b72d0d26/fever-prevention-in-patients-with-acute-vascular-brain-injury-jama-network 2024-09-25T16:36:27+00:00 weekly 0.7 https://trial.medpath.com/news/92c80f67d5d580e8/q-a-promising-treatment-diagnosis-approaches-for-endometrial-cancer-healio 2024-09-25T16:24:26+00:00 weekly 0.7 https://trial.medpath.com/news/1289f3bb91815c0a/opm-announces-its-first-half-2024-results-and-provides-an-update-on-its-clinical-morningstar 2024-09-25T16:19:52+00:00 weekly 0.7 https://trial.medpath.com/news/6b18287b80ea6e9c/why-do-obesity-drugs-seem-to-treat-so-many-other-ailments-nature 2024-09-25T16:10:18+00:00 weekly 0.7 https://trial.medpath.com/news/804dff6532f42efb/groundbreaking-trial-launches-for-everyone-with-ewing-sarcoma-cancer-news 2024-09-25T16:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/4dd81d47a16de4de/phaxiam-provides-business-and-financial-update-for-the-first-half-of-2024-globenewswire 2024-09-25T15:56:37+00:00 weekly 0.7 https://trial.medpath.com/news/cc63fffedc436245/lung-recruitment-before-surfactant-administration-in-extremely-preterm-neonates-jama-network 2024-09-25T15:30:19+00:00 weekly 0.7 https://trial.medpath.com/news/fb9f75f00ba825a4/semaglutide-and-opioid-overdose-risk-in-patients-with-type-2-diabetes-and-opioid-use-disorder 2024-09-25T15:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/fe5b2bce9ad9cd3b/could-ozempic-help-prevent-opioid-overdoses 2024-09-25T15:09:58+00:00 weekly 0.7 https://trial.medpath.com/news/440c041af68e847d/in-bronchiectasis-cathepsin-c-inhibitor-reduces-exacerbation-risk-pulmonology-advisor 2024-09-25T15:05:58+00:00 weekly 0.7 https://trial.medpath.com/news/e9caeeae222cc5c3/immunotherapy-may-not-benefit-all-gastroesophageal-cancer-patients-fda-staff-says 2024-09-25T14:48:47+00:00 weekly 0.7 https://trial.medpath.com/news/efdd6af7333ac58f/combination-treatment-aids-immunotherapies-to-target-non-responsive-lung-cancer-tumors 2024-09-25T14:47:34+00:00 weekly 0.7 https://trial.medpath.com/news/5e5fb2afd428fbfc/spinogenix-announces-launch-of-a-phase-2-clinical-trial-evaluating-spg302-for-the-morningstar 2024-09-25T14:21:08+00:00 weekly 0.7 https://trial.medpath.com/news/79304ed9b1f92a54/shield-therapeutics-announces-promising-paediatric-trial-results-halifax-market-news 2024-09-25T14:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/d9fcc7855f14eb4b/fda-considers-narrowing-label-of-pd-1-drugs-in-stomach-cancer-ahead-of-adcomm-meeting 2024-09-25T13:47:39+00:00 weekly 0.7 https://trial.medpath.com/news/5e393147c9679a25/merck-s-keytruda-combo-fails-in-phase-iii-colorectal-cancer-study-biospace 2024-09-25T13:11:54+00:00 weekly 0.7 https://trial.medpath.com/news/4a2bf572df232904/golfers-against-cancer-denver-funds-cu-cancer-center-research-on-pediatric-cancer 2024-09-25T12:39:25+00:00 weekly 0.7 https://trial.medpath.com/news/39606a7f4ccd727b/daehan-nupharm-launches-a-new-influenza-treatment-kbr 2024-09-25T12:35:58+00:00 weekly 0.7 https://trial.medpath.com/news/68375dca84cca87d/ferring-presents-efficacy-and-safety-data-from-two-phase-3-studies-for-investigational 2024-09-25T12:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/9ecd7d3f702a15fc/heron-therapeutics-announces-fda-approval-of-the-prior-approval-supplement-application 2024-09-25T12:03:05+00:00 weekly 0.7 https://trial.medpath.com/news/7aee2a1074a4dc01/durect-corporation-announces-phase-3-registrational-trial-design-for-larsucosterol-in 2024-09-25T12:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/87a92a69533da0ba/new-research-advances-understanding-of-multiple-myeloma-precursor-diseases-mgus-and-smm 2024-09-25T11:25:02+00:00 weekly 0.7 https://trial.medpath.com/news/d80698ed00c077c2/merck-provides-update-on-phase-3-keyform-007-trial-evaluating-investigational-fixed 2024-09-25T11:20:14+00:00 weekly 0.7 https://trial.medpath.com/news/72d857b43e622c43/kyowa-kirin-announces-top-line-data-from-rocatinlimab-phase-3-rocket-horizon-trial 2024-09-25T11:00:51+00:00 weekly 0.7 https://trial.medpath.com/news/f15ae6849ae0303b/novo-grilled-by-senate-phrma-s-ira-win-and-bms-karxt-awaits-approval-biospace 2024-09-25T10:47:08+00:00 weekly 0.7 https://trial.medpath.com/news/3184f21bce6fdc78/sample-size-recalculation-in-three-stage-clinical-trials-and-its-evaluation 2024-09-25T10:39:55+00:00 weekly 0.7 https://trial.medpath.com/news/9e710b188c55f0ea/amgen-s-amgn-drugs-show-promise-in-phase-3-trials-tipranks-com 2024-09-25T10:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/506784a720d00294/reducing-barriers-to-glucose-monitoring-the-regulatory-review 2024-09-25T10:13:19+00:00 weekly 0.7 https://trial.medpath.com/news/7b1ef30fafd78613/genespire-raises-us-52m-in-series-b-round-european-biotechnology-magazine 2024-09-25T09:38:44+00:00 weekly 0.7 https://trial.medpath.com/news/4a1e4c7540fc6635/clinical-trial-disentangles-immune-issues-and-boosts-anti-cancer-effect-of-bone-marrow 2024-09-25T09:23:54+00:00 weekly 0.7 https://trial.medpath.com/news/705c4d7ddac2ff65/experimental-nasal-spray-might-ward-off-multiple-viruses 2024-09-25T09:09:30+00:00 weekly 0.7 https://trial.medpath.com/news/5a687b3d59528c9f/mayo-clinic-expert-outlines-future-of-pharmacogenomics-and-precision-medicine-in-oncology-care 2024-09-25T08:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/70d8d641720ddaeb/nhs-england-fast-tracks-new-life-extending-blood-cancer-treatment-conservative-post 2024-09-25T07:24:45+00:00 weekly 0.7 https://trial.medpath.com/news/a599ebff094ebbcd/biocina-partners-with-engeneic-to-manufacture-novel-nanocell-cancer-therapy 2024-09-25T06:50:06+00:00 weekly 0.7 https://trial.medpath.com/news/d97dde0d7216d8bb/the-last-day-of-trading-in-diamyd-medical-s-warrants-of-series-to-3-is-today 2024-09-25T06:42:34+00:00 weekly 0.7 https://trial.medpath.com/news/a410cdcbf289d6af/shield-therapeutics-hails-paediatric-phase-iii-study-success-aim-stx-otcqx-shief 2024-09-25T06:41:28+00:00 weekly 0.7 https://trial.medpath.com/news/94de57a6a309f75c/epigenetic-drug-development-sees-record-342m-series-a-funding-surge-in-early-2024 2024-09-25T06:38:23+00:00 weekly 0.7 https://trial.medpath.com/news/abb9d0139b7f97e3/capricor-therapeutics-announces-intent-to-file-biologics-license-application-for-full-biospace 2024-09-25T06:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/676290950a89e30a/first-patient-enrolled-in-phase-i-program-in-stk11-mutant-non-small-cell-lung-cancer-at 2024-09-25T06:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/5e902cff9a7e1cb1/steritas-pediatric-glucocorticoid-toxicity-index-applied-by-alder-hey-children-s-nhs 2024-09-25T06:26:33+00:00 weekly 0.7 https://trial.medpath.com/news/a6e6594b248b6074/convergent-therapeutics-announces-first-patient-treated-in-phase-ii-clinical-trial-pr-newswire 2024-09-25T06:05:53+00:00 weekly 0.7 https://trial.medpath.com/news/92476ee9fd35e128/barinthus-bio-initiates-phase-1-clinical-trial-of-vtp-1000-for-the-treatment-of-celiac-disease 2024-09-25T05:59:45+00:00 weekly 0.7 https://trial.medpath.com/news/5c9b3c19d8ce22dc/media-update-eadv-new-data-reinforce-sanofi-s-innovative-approach-and-leadership 2024-09-25T05:52:59+00:00 weekly 0.7 https://trial.medpath.com/news/8dfc62da740fc1c7/new-galderma-data-demonstrating-nemolizumab-s-long-term-efficacy-and-safety-in-atopic 2024-09-25T05:40:53+00:00 weekly 0.7 https://trial.medpath.com/news/1955ecc3efc686cd/amgen-reports-success-for-eczema-and-myasthenia-gravis-treatments-stat-news 2024-09-25T05:12:50+00:00 weekly 0.7 https://trial.medpath.com/news/831b13ec4e03c599/astrazeneca-moffitt-cancer-center-partner-firefly-neuroscience-advances-ai-tech-more 2024-09-25T05:00:08+00:00 weekly 0.7 https://trial.medpath.com/news/4ee8eafd862992fc/nabp-prepares-pharmacies-for-critical-dscsa-compliance-deadline-in-november-2024 2024-09-25T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d65abd0894824728/junshi-biosciences-announces-european-commission-approval-for-marketing-of-toripalimab 2024-09-25T04:28:59+00:00 weekly 0.7 https://trial.medpath.com/news/c057fb8772f3f137/pfizer-voluntarily-withdraws-all-lots-of-sickle-cell-disease-treatment-oxbryta-voxelotor-from-worldwide-markets 2024-09-25T04:09:06+00:00 weekly 0.7 https://trial.medpath.com/news/cb94b7cd6436eab3/sprim-pro-announces-a-novel-and-validated-approach-for-monitoring-infant-growth-from 2024-09-25T03:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/cd391c727d25203a/spine-biopharma-inc-announces-completion-of-enrollment-for-phase-3-clinical-trial-of-sb 2024-09-25T03:13:01+00:00 weekly 0.7 https://trial.medpath.com/news/ce3c5da8ef2fe76f/amgen-stock-slips-3-following-phase-3-data-for-rocatinlimab-uplizna-seeking-alpha 2024-09-25T01:47:06+00:00 weekly 0.7 https://trial.medpath.com/news/86ebe003e7d8aa19/fda-cracks-down-on-counterfeit-ozempic-and-mounjaro-as-illegal-compounding-surges 2024-09-25T01:32:09+00:00 weekly 0.7 https://trial.medpath.com/news/a67694b75285331e/epineuron-announces-health-canada-approval-of-the-peripulsetm-system-for-nerve-regeneration 2024-09-25T01:27:53+00:00 weekly 0.7 https://trial.medpath.com/news/f5d03ad024501fef/enalare-receives-fda-clearance-to-initiate-the-first-phase-1-clinical-study-of-ena-001-to 2024-09-25T01:27:51+00:00 weekly 0.7 https://trial.medpath.com/news/bb0ce55d92f65e70/ground-breaking-covid-19-antiviral-treatment-trial-opens-to-recruitment-nihr 2024-09-25T00:25:14+00:00 weekly 0.7 https://trial.medpath.com/news/dfa87b24d967b34b/piper-sandler-maintains-overweight-rating-on-acelyrin-shares 2024-09-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e69a8e6d4e6855a7/caribou-biosciences-to-present-preclinical-data-on-cb-010-for-lupus-at-acr-convergence-2024 2024-09-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a918e71ff473e456/clinical-trial-helps-fredon-nj-man-find-leukemia-remission-hackensack-meridian-health 2024-09-24T23:55:04+00:00 weekly 0.7 https://trial.medpath.com/news/2db079f31e309d62/rheacell-announces-fda-approval-for-phase-3-study-in-refractory-non-curable-cvu-prleap 2024-09-24T23:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/97ff171163d48ad6/regulatory-approvals-and-governance-nihr 2024-09-24T22:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/9227782b063a8c7d/urogen-pharma-secures-25m-loan-eyes-fda-drug-approval-investing-com 2024-09-24T21:24:39+00:00 weekly 0.7 https://trial.medpath.com/news/439965f2381f53c4/marstacimab-recommended-for-eu-approval-for-hemophilia-a-and-b 2024-09-24T21:07:13+00:00 weekly 0.7 https://trial.medpath.com/news/b03fe342ec9f55b5/fda-gives-lupin-approval-for-bumetanide-injection-drug-store-news 2024-09-24T20:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/c056d8f799bc8b05/a-clinical-trial-has-halted-progression-of-merkel-cell-carcinoma-and-allowed-me-to-pursue 2024-09-24T20:34:41+00:00 weekly 0.7 https://trial.medpath.com/news/3385224aaaf31a65/successful-clinical-trial-for-antibacterial-implants-by-aap-implantate-ag-webdisclosure 2024-09-24T20:23:53+00:00 weekly 0.7 https://trial.medpath.com/news/bea666a9a946290d/tepezza-r-teprotumumab-receives-approval-in-japan-for-the-treatment 2024-09-24T20:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/3c1f2c67c174a16d/enfortumab-vedotin-combo-earns-japanese-approval-for-urothelial-carcinoma 2024-09-24T20:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/4c58d9677469ac8e/umass-chan-researchers-develop-dual-therapeutic-that-holds-promise-as-pancreatic-cancer 2024-09-24T19:59:21+00:00 weekly 0.7 https://trial.medpath.com/news/f59ee02be12342d4/dod-awards-pitt-100m-for-trauma-trials-upmc 2024-09-24T19:32:55+00:00 weekly 0.7 https://trial.medpath.com/news/0438418c3aa556c3/new-data-published-in-jaaos-demonstrates-breakthrough-therapy-zetafuse-yahoo-finance 2024-09-24T19:20:54+00:00 weekly 0.7 https://trial.medpath.com/news/a5f578a7ab35d8e9/eshoo-bill-to-improve-pediatric-drugs-passes-house-unanimously 2024-09-24T19:16:02+00:00 weekly 0.7 https://trial.medpath.com/news/1351e30dd731ef8c/nxera-pharma-receives-approval-of-quviviq-daridorexant-25-and-50-mg-in-japan-for-the 2024-09-24T19:13:11+00:00 weekly 0.7 https://trial.medpath.com/news/ce5648a0d143492d/iomab-b-leads-to-more-durable-responses-vs-allohct-in-aml-treatment 2024-09-24T19:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/477c6a72e141328c/cutting-edge-multi-arm-octopus-trial-continues-to-progress-well-neurologylive 2024-09-24T19:09:02+00:00 weekly 0.7 https://trial.medpath.com/news/213afa0b51b9d146/recon-japan-approves-lilly-s-alzheimer-s-drug-mhra-seeks-applicants-for-ai-airlock 2024-09-24T19:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/a4295d2eb91342e4/clinical-research-network-nihr 2024-09-24T18:55:01+00:00 weekly 0.7 https://trial.medpath.com/news/e588299aa8167df7/lipidor-ab-announces-first-patient-enrolled-in-phase-iii-study-of-akp02g2-for-topical 2024-09-24T18:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/5ace94953e717f0c/hesperos-provides-support-for-an-investigational-product-for-a-phase-ii-clinical-trial-with-its 2024-09-24T18:39:28+00:00 weekly 0.7 https://trial.medpath.com/news/dd98bda33a77597d/the-odyssey-of-homer-comparative-effectiveness-research-on-medication-for-opioid-use 2024-09-24T18:30:56+00:00 weekly 0.7 https://trial.medpath.com/news/0e0f4cca0e9147f3/partiqol-trial-proton-therapy-vs-imrt-for-localized-prostate-cancer-jason-efstathiou 2024-09-24T18:14:23+00:00 weekly 0.7 https://trial.medpath.com/news/b6b9a48efe69af9c/zkr-orthopedics-performs-first-u-s-patella-lift-procedure-initiating-fda-trial-biospace 2024-09-24T18:12:42+00:00 weekly 0.7 https://trial.medpath.com/news/bfc1b7b8e3b440f4/b-braun-medical-receives-fda-clearance-for-introcan-safety-r-2-deep-access-iv-catheter 2024-09-24T18:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/2b97adcc57c1ccba/the-role-of-surgery-continues-to-evolve-in-seminoma-urology-times 2024-09-24T18:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/ed782cf5612fac33/researchers-publish-critical-examination-of-new-brain-tumor-drug-medical-xpress 2024-09-24T17:54:06+00:00 weekly 0.7 https://trial.medpath.com/news/076f81f516a772d4/georgiamune-announces-first-participant-dosed-in-first-in-class-phase-1-healthy 2024-09-24T17:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/a863b276e5201097/aurinia-announces-japan-approval-of-lupkynis-r-voclosporin-to-treat-lupus-nephritis 2024-09-24T17:50:59+00:00 weekly 0.7 https://trial.medpath.com/news/5d2b234513006b5d/senseonics-stock-down-despite-new-fda-approval-for-eversense-365-yahoo-finance 2024-09-24T17:47:35+00:00 weekly 0.7 https://trial.medpath.com/news/4d92b677fe2fa995/transgene-to-report-major-clinical-data-before-the-end-of-2024-confirmed-financial 2024-09-24T17:38:02+00:00 weekly 0.7 https://trial.medpath.com/news/87bf2e0c4e460e64/inexpensive-drug-can-prevent-cerebral-palsy-in-premature-babies-cochrane 2024-09-24T17:26:16+00:00 weekly 0.7 https://trial.medpath.com/news/bfa1aba460065add/renal-cancer-clinical-trial-pipeline-appears-robust-with-75-key-pharma-companies 2024-09-24T17:17:35+00:00 weekly 0.7 https://trial.medpath.com/news/281db56edef79d90/fda-accepts-roflumilast-s-snda-to-treat-scalp-and-body-psoriasis-in-adolescents-adults 2024-09-24T17:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/9739977b79d6737c/cerapedics-i-factor-p-15-peptide-enhanced-bone-graft-a-trusted-choice-ortho-spine-news 2024-09-24T16:50:06+00:00 weekly 0.7 https://trial.medpath.com/news/ba58634da906ec47/clene-granted-in-person-fda-meeting-on-cnm-au8-for-als-als-news-today 2024-09-24T16:17:55+00:00 weekly 0.7 https://trial.medpath.com/news/23b2b8e7d51b5f5c/lilly-s-kisunlatm-donanemab-azbt-approved-in-japan-for-the-treatment-of-early-pr-newswire 2024-09-24T16:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/6ae5f5660d59d108/re-cognition-health-usa-achieves-gcsa-clinical-trial-site-certification-contract-pharma 2024-09-24T15:45:43+00:00 weekly 0.7 https://trial.medpath.com/news/b9e0304e8ff5c6d4/enrollment-complete-of-phase-2b-of-siglec-study-to-assess-safety-and-efficacy-of-avd-104 2024-09-24T15:14:04+00:00 weekly 0.7 https://trial.medpath.com/news/2c15742428a542f3/new-weight-loss-biotech-metsera-stuns-with-7-5-weight-loss-few-side-effects 2024-09-24T15:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/c6b11d58e7a44aa5/nevro-wins-fda-nod-for-ai-driven-spinal-cord-stimulation-tech-massdevice 2024-09-24T15:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/cb6f38c0af901fe5/ainos-spotlighted-in-water-tower-research-report-on-veldona-clinical-study-for-stock-titan 2024-09-24T15:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/2fec68ec13286c1c/neurosense-therapeutics-granted-key-u-s-patent-for-novel-primec-formulation-its-lead 2024-09-24T14:46:58+00:00 weekly 0.7 https://trial.medpath.com/news/efba11a8bea10206/alxn2220-for-attr-amyloidosis-with-cardiomyopathy-granted-fast-track-designation 2024-09-24T14:46:50+00:00 weekly 0.7 https://trial.medpath.com/news/8422a2c6666a42f5/combination-targeted-therapy-produces-durable-remissions-in-some-patients-the-asco-post 2024-09-24T14:30:19+00:00 weekly 0.7 https://trial.medpath.com/news/29f38c3ff2e51e02/nomic-r-and-parker-institute-for-cancer-immunotherapy-pici-launch-large-scale-protein 2024-09-24T13:45:19+00:00 weekly 0.7 https://trial.medpath.com/news/ff55bb2ce9255ca1/china-medical-system-new-drug-application-for-vitiligo-indication-of-ruxolitinib-phosphate 2024-09-24T13:39:28+00:00 weekly 0.7 https://trial.medpath.com/news/483d337d30120e6d/cardiol-therapeutics-reaches-target-enrollment-for-phase-ii-acute-myocarditis-trial 2024-09-24T13:13:16+00:00 weekly 0.7 https://trial.medpath.com/news/b9cfec6ea568ccf4/neoadjuvant-immunotherapy-for-dmmr-and-pmmr-colorectal-cancers-nature 2024-09-24T13:12:25+00:00 weekly 0.7 https://trial.medpath.com/news/708ff854e7aa1196/clinical-trial-results-show-low-intensity-therapy-can-achieve-positive-outcomes-for-certain 2024-09-24T13:01:12+00:00 weekly 0.7 https://trial.medpath.com/news/6eb8342a33eff286/synergia-implants-first-patients-with-neurostimulator-for-epilepsy-treatment 2024-09-24T12:53:46+00:00 weekly 0.7 https://trial.medpath.com/news/78cacc2c319e87c7/low-intensity-repetitive-transcranial-magnetic-stimulation-enhances-myelin-repair-in-pre 2024-09-24T12:50:50+00:00 weekly 0.7 https://trial.medpath.com/news/12d96221aea89e48/cassava-sciences-announces-completion-of-an-interim-safety-review-of-oral-simufilam-on 2024-09-24T12:41:41+00:00 weekly 0.7 https://trial.medpath.com/news/9f16b5f207274398/psychedelic-therapies-are-coming-to-europe-but-face-barriers-before-reaching-patients 2024-09-24T12:39:02+00:00 weekly 0.7 https://trial.medpath.com/news/6da28e6195ff9af7/enlivex-announces-positive-dsmb-recommendation-to-initiate-globenewswire 2024-09-24T12:36:23+00:00 weekly 0.7 https://trial.medpath.com/news/649241763fcf29af/cytodyn-announces-preliminary-findings-in-study-with-smc-laboratories 2024-09-24T12:30:46+00:00 weekly 0.7 https://trial.medpath.com/news/73dc62e1750c5c3c/aurion-biotech-launches-vyznova-r-neltependocel-in-japan-for-the-treatment-of-bullous 2024-09-24T12:28:06+00:00 weekly 0.7 https://trial.medpath.com/news/0c02356479062c3e/ksq-therapeutics-announces-fda-clearance-of-ind-application-for-ksq-004ex-a-crispr 2024-09-24T12:23:20+00:00 weekly 0.7 https://trial.medpath.com/news/71d9e853959b428b/cpec-phase-ii-is-going-to-start-finance-minister-aaj-news 2024-09-24T12:17:03+00:00 weekly 0.7 https://trial.medpath.com/news/dfc2b3c1da689696/unity-biotechnology-to-host-in-person-ophthalmology-day-in-new-york-on-tuesday 2024-09-24T12:12:27+00:00 weekly 0.7 https://trial.medpath.com/news/e16059140095b042/univo-irb-launches-canadian-research-ethics-board-review-services-for-clinical-trials-in 2024-09-24T12:11:54+00:00 weekly 0.7 https://trial.medpath.com/news/25f4d897b6b581c1/silexion-therapeutics-announces-significant-new-data-from-phase-2-trial-of-lodertm-in 2024-09-24T11:48:30+00:00 weekly 0.7 https://trial.medpath.com/news/e4d82686ba6381e7/zevra-therapeutics-to-present-top-line-data-from-the-phase-2-clinical-trial-of-kp1077-for 2024-09-24T11:48:24+00:00 weekly 0.7 https://trial.medpath.com/news/4c11badc5d5c962a/wave-life-sciences-announces-positive-interim-data-from-forward-53-clinical-trial 2024-09-24T11:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/94110e60d2253ed5/biogen-ucb-get-the-lupus-data-they-ve-waited-two-decades-for-biopharma-dive 2024-09-24T11:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/f2456f16488e8f02/united-therapeutics-to-feature-clinical-data-across-its-commercial-and-development 2024-09-24T11:04:16+00:00 weekly 0.7 https://trial.medpath.com/news/ea216b612a1048fe/mre-and-te-show-limited-accuracy-in-detecting-advanced-liver-fibrosis-in-pediatric-masld-patients 2024-09-24T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dcb917a3fb6bc0e5/new-funding-to-better-understand-causes-of-rare-cancers-and-their-responses-to-targeted-therapy 2024-09-24T10:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/a79c4bedd3b87894/a-cluster-randomized-study-of-technology-assisted-health-coaching-for-weight 2024-09-24T10:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/af688a2db318ce33/lsu-lcmc-health-cancer-center-experts-discuss-advances-in-research-and-goals-for-a 2024-09-24T10:02:24+00:00 weekly 0.7 https://trial.medpath.com/news/4438e2369083e0cc/senate-confronts-novo-nordisk-over-semaglutide-pricing-demands-u-s-price-parity-with-europe 2024-09-24T09:46:54+00:00 weekly 0.7 https://trial.medpath.com/news/416c6169dfd9abab/popular-diabetes-drug-metformin-may-slow-aging-study-finds-cbs-news 2024-09-24T09:38:36+00:00 weekly 0.7 https://trial.medpath.com/news/03f46a74628dee93/psilocybin-may-curb-mental-illness-that-leads-to-eating-disorders 2024-09-24T09:09:27+00:00 weekly 0.7 https://trial.medpath.com/news/2173b0da93b886d7/algotx-announces-last-patient-last-visit-in-international-phase-ii-trial-of-atx01-in-morningstar 2024-09-24T07:53:57+00:00 weekly 0.7 https://trial.medpath.com/news/a3928aba775c8498/experts-discuss-treatment-strategies-and-challenges-in-managing-chronic-gvhd-after-stem-cell-transplantation 2024-09-24T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c573f8d270227184/chugai-receives-approvals-for-additional-indication-of-evrysdi-in-pre-symptomatic-spinal 2024-09-24T06:38:34+00:00 weekly 0.7 https://trial.medpath.com/news/1a1245e9bc5c2a04/medicare-drug-price-negotiations-pose-complex-challenges-for-community-oncology-practices 2024-09-24T06:26:29+00:00 weekly 0.7 https://trial.medpath.com/news/eec54bcc23853284/why-industry-must-design-alzheimer-s-trials-to-include-people-with-down-syndrome 2024-09-24T06:14:40+00:00 weekly 0.7 https://trial.medpath.com/news/46a6b54ed17544b0/gsk-s-menveo-meningococcal-vaccine-in-new-single-vial-fully-liquid-presentation-receives 2024-09-24T06:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/f113afe6bea19c52/nfl-legend-brett-favre-reveals-parkinson-s-disease-diagnosis-amid-congressional-testimony 2024-09-24T05:22:45+00:00 weekly 0.7 https://trial.medpath.com/news/c7bd58628157ef0a/basilea-initiates-clinical-phase-3-study-with-antifungal-globenewswire 2024-09-24T05:21:19+00:00 weekly 0.7 https://trial.medpath.com/news/8f9c4a3d74c79f7e/santhera-announces-acceptance-by-swissmedic-of-marketing-authorization-application-for 2024-09-24T05:10:16+00:00 weekly 0.7 https://trial.medpath.com/news/d01ff947ca34e933/opensafely-platform-revolutionizes-big-data-medical-research-with-enhanced-privacy-protection 2024-09-24T05:01:50+00:00 weekly 0.7 https://trial.medpath.com/news/2f5c8b816273d9a2/amr-accelerator-urges-long-term-funding-european-biotechnology-magazine 2024-09-24T04:11:22+00:00 weekly 0.7 https://trial.medpath.com/news/4f03fead4a1889c4/lighting-the-way-to-pain-relief-drug-discovery-news 2024-09-24T04:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/052bf67e02ef181f/leading-neuro-oncologist-emphasizes-importance-of-proactive-mentorship-in-brain-cancer-research 2024-09-24T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a70920bc990c581f/tonix-pharmaceuticals-announces-data-presentations-on-tnx-102-sl-for-fibromyalgia-at 2024-09-24T03:56:28+00:00 weekly 0.7 https://trial.medpath.com/news/6b9d34f5b46be984/new-model-identifies-cancer-patients-at-high-risk-for-er-visits-during-clinical-trials 2024-09-24T02:51:43+00:00 weekly 0.7 https://trial.medpath.com/news/c4dea5e76e447a93/reconsidering-rems-mandate-may-improve-car-t-cell-therapy-accessibility 2024-09-24T02:04:14+00:00 weekly 0.7 https://trial.medpath.com/news/51d620b8b4bec277/detecting-clear-cell-renal-cell-carcinoma-use-of-zr-89-girentuximab-pet-ct-imaging 2024-09-24T01:56:15+00:00 weekly 0.7 https://trial.medpath.com/news/2eb36a5db0c2eab8/south-korean-study-finds-fecal-microbiota-transplants-may-help-patients-with-dark-daily 2024-09-24T01:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/8c229dffcec33ea8/neurosense-regains-compliance-with-nasdaq-minimum-bid-price-rule 2024-09-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3fd2202a4b066024/roche-unveils-tags-technology-revolutionary-multi-pathogen-detection-system-for-infectious-diseases 2024-09-23T23:17:16+00:00 weekly 0.7 https://trial.medpath.com/news/46ffc9fbd98b4b37/fda-accepts-leo-pharmas-filing-of-delgocitinib-cream-new-drug-application-for-the-treatment-of-chronic-hand-eczema 2024-09-23T23:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/5f1025ab6d4d7296/cenna-biosciences-receives-nih-nia-phase-ii-sbir-award-for-the-early-clinical-yahoo-finance 2024-09-23T22:53:14+00:00 weekly 0.7 https://trial.medpath.com/news/8c3cf43fb7c171f8/effectiveness-of-rimegepant-further-displayed-in-pooled-phase-3-analysis-neurologylive 2024-09-23T22:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/66573f63945cc5e5/former-orphazyme-drug-arimoclomol-approved-by-fda-medwatch 2024-09-23T21:58:28+00:00 weekly 0.7 https://trial.medpath.com/news/21f803f5eef75eaa/vicebio-secures-100m-to-advance-rsv-and-hmpv-vaccine-combo-to-phase-i 2024-09-23T21:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/77374ce506f962d2/aptar-s-n-sorb-nitrosamine-mitigation-solution-accepted-to-us-fda-s-emerging-technology-program 2024-09-23T21:11:53+00:00 weekly 0.7 https://trial.medpath.com/news/52dfbbe7ed6589d2/dbv-technologies-completes-screening-for-the-vitesse-phase-3-clinical-trial 2024-09-23T21:04:11+00:00 weekly 0.7 https://trial.medpath.com/news/6e7003cd086ab8a0/clinical-trial-supports-adding-ruxolitinib-to-tyrosine-kinase-inhibitors-for-chronic-myeloid-leukemia 2024-09-23T21:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/f58498a4b54c698d/frontiers-effects-of-active-breaks-on-educational-achievement-in-children-with-and-without-adhd 2024-09-23T20:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/2ccb9938568bce23/orthopaedic-surgery-supports-pediatric-patients-through-cancer-diagnosis-treatment 2024-09-23T20:56:46+00:00 weekly 0.7 https://trial.medpath.com/news/9fdb43a1a3147079/aavantgarde-bio-doses-first-patient-in-trial-for-usher-syndrome-gene-therapy-aavb-081 2024-09-23T20:30:21+00:00 weekly 0.7 https://trial.medpath.com/news/0862e20f0f368598/watchful-waiting-noninferior-to-bcg-for-resected-high-grade-pt1-bladder-cancer 2024-09-23T20:14:37+00:00 weekly 0.7 https://trial.medpath.com/news/3b0c234766213118/transdermal-estradiol-may-offer-another-option-for-high-risk-prostate-cancer 2024-09-23T20:14:36+00:00 weekly 0.7 https://trial.medpath.com/news/dd37df106eeb8686/mercy-now-offering-proton-beam-clinical-trials-spectrum-news 2024-09-23T18:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/086dfcd7132b7f43/biohaven-achieves-positive-topline-results-in-pivotal-study-of-troriluzole-in-pr-newswire 2024-09-23T18:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/7a9c89c5d35c2ae6/wicker-celebrates-new-innovation-hub-tackling-rare-diseases-u-s-senator-roger 2024-09-23T17:27:25+00:00 weekly 0.7 https://trial.medpath.com/news/1c92df2f617ec843/apellis-stock-down-as-eye-drug-faces-third-chmp-rejection-in-the-eu-yahoo-finance 2024-09-23T17:25:36+00:00 weekly 0.7 https://trial.medpath.com/news/54da6b26f5be689d/pancreatic-cancer-the-clinical-trial-landscape-and-progress-for-2024 2024-09-23T17:15:35+00:00 weekly 0.7 https://trial.medpath.com/news/1e4733fb3e1e6c17/short-course-of-treatment-with-rns60-extends-survival-in-als-als-news-today 2024-09-23T16:50:04+00:00 weekly 0.7 https://trial.medpath.com/news/452ea478738dabd3/dundee-research-reveals-breakthrough-for-tough-cancers-mirage-news 2024-09-23T16:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/a2fddb4a8b9d5fd1/patient-directed-education-to-promote-deprescribing-a-nonrandomized-clinical-trial 2024-09-23T16:14:33+00:00 weekly 0.7 https://trial.medpath.com/news/d9ba56dd3115ec19/us-whooping-cough-cases-rising-especially-in-teens-cdc-says-empr-com 2024-09-23T16:03:58+00:00 weekly 0.7 https://trial.medpath.com/news/02195d88a394d5a5/ideaya-biosciences-announces-positive-interim-phase-2-data-for-darovasertib-pr-newswire 2024-09-23T16:02:12+00:00 weekly 0.7 https://trial.medpath.com/news/2f8780dd7fbb1375/novel-approach-to-evaluate-the-role-of-selexipag-in-pulmonary-arterial-hypertension 2024-09-23T15:27:59+00:00 weekly 0.7 https://trial.medpath.com/news/3460e88d98154490/first-line-serplulimab-receives-positive-chmp-opinion-for-es-sclc-onclive 2024-09-23T15:23:51+00:00 weekly 0.7 https://trial.medpath.com/news/0584427129341bb6/cidara-therapeutics-announces-first-subjects-dosed-in-phase-2b-navigate-trial 2024-09-23T15:09:20+00:00 weekly 0.7 https://trial.medpath.com/news/12b3032e03c43491/black-diamond-therapeutics-announces-initial-phase-2-data-demonstrating-robust-biospace 2024-09-23T15:09:20+00:00 weekly 0.7 https://trial.medpath.com/news/f65ef5f823e4fada/ca-pharma-co-reports-positive-phase-3-data-for-schizophrenia-treatment 2024-09-23T14:58:55+00:00 weekly 0.7 https://trial.medpath.com/news/0331593a09ab9614/cu-cancer-center-research-tests-two-drug-treatment-for-progressive-thyroid-cancer 2024-09-23T14:56:23+00:00 weekly 0.7 https://trial.medpath.com/news/d0e0761d668980e7/astrazeneca-pharma-gets-nod-to-launch-cancer-drug-durvalumab-in-india-cnbc-tv18 2024-09-23T14:52:48+00:00 weekly 0.7 https://trial.medpath.com/news/0f41c1c49d0e0232/fragile-x-held-him-back-an-experimental-drug-is-helping-him-break-free-npr 2024-09-23T14:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/c378f41376e8353a/charlotte-dna-repair-research-may-influence-cancer-clinical-trials 2024-09-23T14:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/4aa2a1ef43423f0a/apps-offer-a-unique-lens-to-myeloma-care-oncology-nursing-news 2024-09-23T14:09:35+00:00 weekly 0.7 https://trial.medpath.com/news/9bd93fb748088953/university-of-cincinnati-cancer-center-hosts-phase-3-prostate-cancer-trial 2024-09-23T13:52:07+00:00 weekly 0.7 https://trial.medpath.com/news/45935add9916d2b0/new-ai-model-enhances-clinical-trial-approval-predictions-by-quantifying-uncertainty 2024-09-23T13:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/dcadd7093e8ceaaa/us-filing-accepted-for-new-growth-hope-for-leo-pharma-medwatch 2024-09-23T13:48:48+00:00 weekly 0.7 https://trial.medpath.com/news/40ea5fb605a9917b/sylvester-researchers-expand-ovarian-cancer-study-to-africa 2024-09-23T13:45:30+00:00 weekly 0.7 https://trial.medpath.com/news/e12a1abf5ee47581/realta-life-sciences-announces-first-patient-dosed-in-phase-2-study-evaluating-rls-0071 2024-09-23T13:20:37+00:00 weekly 0.7 https://trial.medpath.com/news/c2840db6e8fa6901/lantern-pharma-announces-three-u-s-fda-rare-pediatric-disease-designations-granted 2024-09-23T13:20:37+00:00 weekly 0.7 https://trial.medpath.com/news/ae871db482104bce/readout-newsletter-biohaven-daiichi-sankyo-astrazeneca-news-stat-news 2024-09-23T13:17:16+00:00 weekly 0.7 https://trial.medpath.com/news/2e61cb9b29b2b329/bonafide-r-health-launches-thermellatm-the-first-and-only-hormone-free-prescription 2024-09-23T13:06:58+00:00 weekly 0.7 https://trial.medpath.com/news/9e5a76a3d2ba2c2d/kazia-therapeutics-announces-presentation-of-evt801-clinical-data-at-15th-biennial-stock-titan 2024-09-23T13:00:12+00:00 weekly 0.7 https://trial.medpath.com/news/4697fc669612f98f/vistagen-initiates-palisade-4-phase-3-study-of-fasedienol-for-the-acute-treatment-stock-titan 2024-09-23T12:50:41+00:00 weekly 0.7 https://trial.medpath.com/news/3248893b9496439c/immusoft-to-announce-positive-phase-1-data-for-first-engineered-b-cell-therapy-in-a-clinical-trial 2024-09-23T12:30:49+00:00 weekly 0.7 https://trial.medpath.com/news/1862a1c803e632ea/rivus-pharmaceuticals-to-present-new-data-from-phase-2a-humain-trial-of-hu6-pr-newswire 2024-09-23T12:23:39+00:00 weekly 0.7 https://trial.medpath.com/news/5985fbd1d7b28596/therivatm-biologics-achieves-target-patient-enrollment-in-the-virage-phase-2b-trial-of 2024-09-23T12:17:24+00:00 weekly 0.7 https://trial.medpath.com/news/a85698e4717ac844/oryzon-presents-the-final-data-from-portico-a-global-phase-iib-vafidemstat-trial-in 2024-09-23T12:14:43+00:00 weekly 0.7 https://trial.medpath.com/news/1da48ffc7e23b754/assembly-biosciences-reports-positive-interim-phase-1a-results-from-clinical-trial 2024-09-23T12:14:43+00:00 weekly 0.7 https://trial.medpath.com/news/c2be6aeda35e216d/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439 2024-09-23T12:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/6decfe3c8cc912a4/ipsen-s-kayfanda-r-odevixibat-approved-in-european-union-for-cholestatic-pruritus-in 2024-09-23T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c17c6f05ecf2267e/elevation-oncology-receives-fast-track-designation-from-the-fda-for-eo-3021-for-pr-newswire 2024-09-23T11:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/c78e1ea34d89946d/priovant-therapeutics-announces-receipt-of-fast-track-designation-from-fda-for-pr-newswire 2024-09-23T11:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/924b6601eb02a1ad/uniqure-announces-orphan-drug-designation-granted-globenewswire 2024-09-23T11:20:14+00:00 weekly 0.7 https://trial.medpath.com/news/df322526e40eb4c1/heidelberg-pharma-announces-new-clinical-data-on-lead-atac-candidate-hdp-101-to-be 2024-09-23T11:08:07+00:00 weekly 0.7 https://trial.medpath.com/news/03900f7d9b025a48/prestige-biopharma-secures-ec-approval-for-herceptin-biosimilar-tuznue-kbr 2024-09-23T11:04:45+00:00 weekly 0.7 https://trial.medpath.com/news/5af18344f301574f/takeda-s-fruquintinib-gains-mhra-approval-for-colorectal-cancer 2024-09-23T11:02:29+00:00 weekly 0.7 https://trial.medpath.com/news/63da0f04cf21b918/alkermes-to-present-positive-clinical-data-from-phase-1b-study-of-alks-2680-in-patients 2024-09-23T11:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/ea957e99506e6444/fda-sirb-mandate-a-chance-to-reassess-site-performance-contract-pharma 2024-09-23T11:01:14+00:00 weekly 0.7 https://trial.medpath.com/news/9ceff137dd8c8b47/effects-of-medicaid-coverage-on-cardiovascular-health-outcomes-the-bmj 2024-09-23T10:25:16+00:00 weekly 0.7 https://trial.medpath.com/news/c87c179b2cc38c9d/therma-bright-investment-portfolio-company-instatin-secures-mountain-west-research 2024-09-23T10:14:18+00:00 weekly 0.7 https://trial.medpath.com/news/0ef02cd7a6c15b77/pdcs-vs-adcs-a-new-frontier-in-targeted-cancer-therapies-and-the-potential-for 2024-09-23T10:12:58+00:00 weekly 0.7 https://trial.medpath.com/news/e2ccf523ba7d0eb5/fda-accepts-leo-pharma-s-filing-of-delgocitinib-cream-new-drug-application-for-the 2024-09-23T10:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/efc404703a41a7ed/could-antidepressants-give-memory-a-boost 2024-09-23T09:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/eacf41ef99af37c8/diabetes-treatment-might-ease-gum-disease-too 2024-09-23T09:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/cdc7d460c3cad4c3/antengene-announces-xpovio-r-selinexor-approved-for-commercialization-in-thailand 2024-09-23T09:02:10+00:00 weekly 0.7 https://trial.medpath.com/news/758a0f941ee35fa1/largest-collection-of-sarcoma-patient-derived-organoids-pave-the-way-for-personalized 2024-09-23T08:57:23+00:00 weekly 0.7 https://trial.medpath.com/news/f758df2d782baa60/new-biological-findings-open-the-door-to-improved-outcomes-for-young-adults-with-sarcoma 2024-09-23T08:14:03+00:00 weekly 0.7 https://trial.medpath.com/news/b89336514c6f1a5f/bajaj-healthcare-soars-7-after-pact-with-european-firm-for-new-api-business-standard 2024-09-23T07:30:39+00:00 weekly 0.7 https://trial.medpath.com/news/5c932bbf4343dba2/medicare-s-2-drug-list-model-could-benefit-38-of-beneficiaries-with-modest-cost-savings 2024-09-23T07:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/d7def657cce89712/ai-shows-promise-and-limitations-across-multiple-cancer-care-applications 2024-09-23T06:00:10+00:00 weekly 0.7 https://trial.medpath.com/news/5a9d0c3463a346b0/relief-therapeutics-announces-2-million-milestone-under-royalty-sales-agreement 2024-09-23T05:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/184d1ef30b750729/innate-pharma-announces-fda-clearance-of-the-ind-for-iph4502-a-nectin-4-adc-to-be 2024-09-23T05:07:18+00:00 weekly 0.7 https://trial.medpath.com/news/15f2f429e5a3c348/ucb-announces-u-s-fda-approvals-for-bimzelx-r-bimekizumab-bkzx-for-the-treatment 2024-09-23T05:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/89a7eca8551673b7/in-trials-a-powerful-magnet-for-zapping-alzheimer-s-away-being-patient 2024-09-23T04:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/2557268cf3235bed/pepgen-to-release-duchenne-muscular-dystrophy-drug-trial-results-in-mid-2024 2024-09-23T03:15:39+00:00 weekly 0.7 https://trial.medpath.com/news/f2607623bb8eca43/hlb-reapply-for-liver-cancer-drug-approval-from-fda-businesskorea 2024-09-23T02:12:42+00:00 weekly 0.7 https://trial.medpath.com/news/a62839698796b282/tumour-response-in-sixth-patient-triggers-additional-recruitment-in-pancreatic-cancer-trial 2024-09-23T00:27:08+00:00 weekly 0.7 https://trial.medpath.com/news/91615f0db35dd5de/synergia-medical-successfully-implants-first-patients-with-nao-vns-system 2024-09-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/80b047d642228329/msd-receives-singapore-health-sciences-authority-hsa-approval-for 2024-09-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a9caa05cb2c550f8/aerify-1-2-trials-evaluating-itepekimab-for-moderate-to-severe-copd-in-former-smokers 2024-09-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4fb24c0db628e64b/cost-utility-and-budget-impact-analysis-of-adding-sglt-2-inhibitors-to-standard-treatment 2024-09-22T23:03:09+00:00 weekly 0.7 https://trial.medpath.com/news/d0b46213a0eb1b8b/proteomics-international-laboratories-ltd-asx-piq-esophageal-cancer-diagnostic 2024-09-22T23:01:20+00:00 weekly 0.7 https://trial.medpath.com/news/8b3ec84cb70264c7/registration-of-cytostatic-effects-on-cultured-cells-in-vitro-and-their-current-significance-pubmed 2024-09-22T22:39:45+00:00 weekly 0.7 https://trial.medpath.com/news/d4db32db5f99c15f/this-immigrant-just-became-a-biotech-billionaire-forbes-australia 2024-09-22T22:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/5b77fbfc5753640d/this-stock-is-crushing-nvidia-s-performance-this-year-is-it-too-late-to-buy 2024-09-22T20:28:40+00:00 weekly 0.7 https://trial.medpath.com/news/a55782dbad4d696d/canaritech-announces-the-launch-of-operations-offering-comprehensive-clinical-trial 2024-09-22T20:09:15+00:00 weekly 0.7 https://trial.medpath.com/news/de7c31b823a18758/ovarian-function-suppression-may-benefit-select-breast-cancer-populations 2024-09-22T19:57:13+00:00 weekly 0.7 https://trial.medpath.com/news/c749d0da69fd68a8/buy-rating-reaffirmed-for-apellis-pharmaceuticals-amid-market-overreaction-and-promising 2024-09-22T17:33:45+00:00 weekly 0.7 https://trial.medpath.com/news/0345fb0b0bb718e7/black-diamond-therapeutics-to-host-webcast-presentation-of-initial-phase-2-bdtx-1535 2024-09-22T16:33:36+00:00 weekly 0.7 https://trial.medpath.com/news/75920d4a93dabee7/most-cancer-drugs-must-now-be-tested-in-paediatric-cancers-unique-pdx-models-can-help-nature 2024-09-22T16:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/07edbddd3981f2de/tapotoclax-demonstrates-safety-yields-anti-leukemic-effects-but-no-responses-in-mds 2024-09-22T16:08:40+00:00 weekly 0.7 https://trial.medpath.com/news/c4b1d8e716a1eee4/epstein-barr-virus-immune-response-specific-to-multiple-sclerosis-relative-to-other 2024-09-22T16:06:42+00:00 weekly 0.7 https://trial.medpath.com/news/a5db1a1887f1e7d8/lunning-evaluates-car-t-cell-therapy-for-asct-eligible-and-ineligible-dlbcl 2024-09-22T15:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/d9b84910f7246a98/faster-identification-of-infants-at-high-risk-of-rop-by-evaluating-the-effects-of-maternal-and 2024-09-22T15:05:07+00:00 weekly 0.7 https://trial.medpath.com/news/a24ddffdadaff219/long-term-data-affirm-enduring-responses-with-teclistamab-in-r-r-multiple-myeloma 2024-09-22T14:10:42+00:00 weekly 0.7 https://trial.medpath.com/news/7a4eff33398a464c/pfspz-vaccine-shows-efficacy-against-p-falciparum-and-malaria-in-women-who-become-pregnant 2024-09-22T13:44:14+00:00 weekly 0.7 https://trial.medpath.com/news/8c12e89628eef236/ideaya-announces-webcast-to-report-interim-phase-2-data-for-darovasertib-and 2024-09-22T13:02:11+00:00 weekly 0.7 https://trial.medpath.com/news/bd49d7ccb39230b3/bwc0977-a-new-approach-to-antimicrobial-resistance-contagion-live 2024-09-22T11:29:14+00:00 weekly 0.7 https://trial.medpath.com/news/cbefa7fd5d10c353/hong-kong-team-to-enrol-3000-patients-to-improve-ai-tool-targeting-cardiovascular-disease 2024-09-22T11:23:41+00:00 weekly 0.7 https://trial.medpath.com/news/513aa555bedf84eb/imaging-study-offers-insights-on-mechanism-behind-bcg-resistance-in-nmibc 2024-09-22T10:17:14+00:00 weekly 0.7 https://trial.medpath.com/news/8ad21fd67481563a/screening-for-colon-cancer-could-expand-with-a-convenient-alternative-if-fda-approves-new 2024-09-22T10:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/54a1d6812eed3a12/whooping-cough-cases-are-soaring-can-infecting-people-help-test-a-better-vaccine 2024-09-22T08:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/3c5bcc109906a1c2/this-week-s-awesome-tech-stories-from-around-the-web-through-september-21 2024-09-22T07:54:57+00:00 weekly 0.7 https://trial.medpath.com/news/dd45ff3b7c2bffd7/men-get-breast-cancer-too-but-they-can-t-always-access-new-drugs-cbc-news 2024-09-22T07:04:19+00:00 weekly 0.7 https://trial.medpath.com/news/9676ff121a12665e/ibcn-2024-molecular-subtypes-and-outcomes-in-the-vesper-trial-urotoday 2024-09-22T07:01:57+00:00 weekly 0.7 https://trial.medpath.com/news/36960c7fb9e775cc/who-evaluates-india-s-top-drug-regulator-vaccine-manufacturing-practices 2024-09-22T07:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/9813a1fe7744b718/oncology-leaders-emphasize-cautious-ai-implementation-to-maintain-physician-trust 2024-09-22T05:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/e9cd243c1f2d6a70/expert-reaction-to-6-month-follow-up-of-phase-2-trial-of-psilocybin-versus-escitalopram-for-depression 2024-09-22T05:43:13+00:00 weekly 0.7 https://trial.medpath.com/news/6c4ee00d547ae4ba/relacorilant-or-surgery-improved-hemostatic-markers-in-cushing-syndrome 2024-09-22T05:08:51+00:00 weekly 0.7 https://trial.medpath.com/news/d6ffe9f4176459d7/comparative-cost-effectiveness-of-atezolizumab-versus-durvalumab-as-first-line 2024-09-22T05:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/a51359e455b50712/end-of-dose-phenomena-observed-with-multiple-sclerosis-medication-ofatumumab 2024-09-22T04:50:53+00:00 weekly 0.7 https://trial.medpath.com/news/21afbecb51876999/study-shows-psychedelic-drug-psilocybin-gives-eurekalert 2024-09-22T02:11:13+00:00 weekly 0.7 https://trial.medpath.com/news/28a459904ee67952/sustained-reductions-of-brain-atrophy-observed-with-s1p-modulator-ozanimod 2024-09-22T01:05:54+00:00 weekly 0.7 https://trial.medpath.com/news/4d053fdbe77cfefe/stealth-biotherapeutics-presents-preclinical-data-on-bevemipretide-s-retinal-delivery-in-amd-models 2024-09-21T22:18:23+00:00 weekly 0.7 https://trial.medpath.com/news/f523f42a66b84504/benefit-of-whole-pelvis-radiation-for-patients-with-muscle-invasive-bladder-cancer 2024-09-21T21:37:11+00:00 weekly 0.7 https://trial.medpath.com/news/9e72703b908bfcdd/expediting-clinical-trial-processes-to-advance-brain-cancer-research 2024-09-21T20:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/dc1f9a7f467afb88/exploring-gprc5d-as-an-important-target-for-multiple-myeloma-cancer-network 2024-09-21T20:50:25+00:00 weekly 0.7 https://trial.medpath.com/news/ea243fcd42bad904/bladder-cancer-breakthroughs-in-sunrise-1-ambassador-and-volga-trials-maria-de-santis 2024-09-21T20:43:53+00:00 weekly 0.7 https://trial.medpath.com/news/cb0051f96eb80325/tiziana-life-sciences-announces-4-million-grant-awarded-by-nih-to-study-anti-cd3-in 2024-09-21T20:28:50+00:00 weekly 0.7 https://trial.medpath.com/news/557f2ed86406d82b/vietnam-launches-vaccination-against-dengue-fever-nationwide-for-first-time-tuoi-tre-news 2024-09-21T19:25:55+00:00 weekly 0.7 https://trial.medpath.com/news/3a98f9e9bac26aed/ibcn-2024-using-urinary-genomic-disease-burden-to-assess-cretostimogene-grenadenorepvec 2024-09-21T18:48:11+00:00 weekly 0.7 https://trial.medpath.com/news/d6318b2750723ca5/teva-presents-new-phase-3-efficacy-safety-and-tolerability-data-from-solaris-trial-stock-titan 2024-09-21T18:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/11feae6572d350e7/fda-approves-isatuximab-plus-vrd-for-newly-diagnosed-transplant-ineligible-multiple-myeloma 2024-09-21T16:53:44+00:00 weekly 0.7 https://trial.medpath.com/news/71908c88bcf464bd/a-randomized-multicenter-phase-3-clinical-trial-evaluating-intracanal-opth 2024-09-21T16:17:42+00:00 weekly 0.7 https://trial.medpath.com/news/629e3bbad3ceace4/disparities-in-time-to-oral-antimyeloma-treatment-shown-in-new-study 2024-09-21T15:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/82e6a973c90b9b68/btk-inhibitor-therapy-can-be-stopped-in-cll-targeted-oncology 2024-09-21T15:58:07+00:00 weekly 0.7 https://trial.medpath.com/news/826ec2106edbffbe/efficacy-of-cilta-cel-is-maintained-in-early-relapsed-multiple-myeloma-targeted-oncology 2024-09-21T15:58:07+00:00 weekly 0.7 https://trial.medpath.com/news/70c49a35c649be91/ectrims-2024-high-dose-vitamin-d-can-help-delay-progression-to-ms 2024-09-21T15:47:20+00:00 weekly 0.7 https://trial.medpath.com/news/653b719a21c103b6/niger-latest-african-country-to-launch-malaria-vaccine-medical-xpress 2024-09-21T15:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/752f27392ad5301b/lenalidomide-obinutuzumab-combo-yields-promising-results-in-relapsed-nhl 2024-09-21T14:26:19+00:00 weekly 0.7 https://trial.medpath.com/news/6f0e139447c96683/fight-retinal-blindness-spain-report-3-clinical-outcomes-of-vascular-endothelial-growth 2024-09-21T14:08:21+00:00 weekly 0.7 https://trial.medpath.com/news/e3ca2e81b55c03eb/armour-s-mononine-monoclonal-factor-ix-approved-by-fda-pink-sheet 2024-09-21T14:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/975b09bb02dc9c74/ibcn-2024-eg-70-detalimogene-voraplasmid-a-novel-non-viral-intravesical-gene 2024-09-21T14:02:58+00:00 weekly 0.7 https://trial.medpath.com/news/037fd36d9e4e6d10/new-clinical-trial-in-kenya-could-move-needle-in-cancer-treatment-the-standard-health 2024-09-21T13:48:09+00:00 weekly 0.7 https://trial.medpath.com/news/0b8c5a656820b376/gene-and-cell-therapy-approaches-hold-promise-for-usher-syndrome-cgtlive-r 2024-09-21T13:13:28+00:00 weekly 0.7 https://trial.medpath.com/news/d44972accdabd6aa/ozempic-glp-1-drugs-may-prevent-3400-heart-attacks-strokes-a-year-healthline 2024-09-21T12:23:19+00:00 weekly 0.7 https://trial.medpath.com/news/46fd72648698971c/expert-dermatologist-outlines-key-diagnostic-criteria-for-urticaria-at-maui-derm-conference 2024-09-21T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/29e29129f8bc881f/study-highlights-variable-efficacy-of-aspirin-dosing-during-pregnancy 2024-09-21T11:35:23+00:00 weekly 0.7 https://trial.medpath.com/news/eae8daa9d2635f76/pharma-stock-roundup-fda-approvals-for-lly-mrk-azn-jnj-drugs-yahoo-finance 2024-09-21T11:12:45+00:00 weekly 0.7 https://trial.medpath.com/news/a3a397b5925ea2d9/president-and-ceo-harris-todd-sold-394441-worth-of-shares-16307-units-at-24-19 2024-09-21T10:44:46+00:00 weekly 0.7 https://trial.medpath.com/news/f0f41350784ac62c/high-throughput-identification-of-repurposable-neuroactive-drugs-with-potent-anti-nature 2024-09-21T10:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/810442400358ac12/first-line-combo-yields-strong-results-in-advanced-sarcoma 2024-09-21T10:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/b49aa1281b04f4a0/chief-medical-officer-conner-edward-r-exercised-4790-shares-at-a-strike-of-4-20-and-sold 2024-09-21T09:51:57+00:00 weekly 0.7 https://trial.medpath.com/news/acc50e537c8515a7/fda-approval-propels-zvra-to-52-week-high-adma-cprx-tvtx-also-reach-new-peaks 2024-09-21T08:27:23+00:00 weekly 0.7 https://trial.medpath.com/news/358b6664afa206ea/ncpa-intensifies-campaign-for-pbm-reform-as-congressional-deadline-looms 2024-09-21T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6bc668ad6b22b2c9/study-shingles-reactivation-could-occur-in-rare-cases-following-rzv-pharmacy-times 2024-09-21T07:26:01+00:00 weekly 0.7 https://trial.medpath.com/news/23b0b3724aab25a6/capivasertib-shows-promise-in-er-her2-metastatic-breast-cancer-with-pik3ca-mutations 2024-09-21T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/052e2369de22f006/global-metabolic-disruption-discovered-in-sma-patients-n-acetylneuraminic-acid-shows-treatment-potential 2024-09-21T06:28:00+00:00 weekly 0.7 https://trial.medpath.com/news/d6e636bf3d002e2d/apellis-shares-dip-as-mizuho-cuts-price-target-keeps-neutral-rating-investing-com-canada 2024-09-21T05:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/d4589f11299b2722/biohaven-announces-conference-call-to-discuss-topline-pivotal-study-results-in-pr-newswire 2024-09-21T05:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/74d21d136bb4798b/novel-pan-immune-inflammation-nomogram-shows-promise-in-predicting-epithelial-ovarian-cancer-outcomes 2024-09-21T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/03b5760d8980d66c/rachna-shroff-on-advanced-hepatocellular-carcinoma-anlotinib-plus-penpulimab-vs-sorafenib 2024-09-21T04:54:50+00:00 weekly 0.7 https://trial.medpath.com/news/0f3320a7e1c54cf9/simvastatin-fails-to-reduce-disease-progression-in-phase-3-ms-stat2-trial-of-secondary 2024-09-21T04:41:10+00:00 weekly 0.7 https://trial.medpath.com/news/688f6f45ae743903/university-of-arkansas-for-medical-sciences-receives-2-2-million-grant-to-study-efferocytosis 2024-09-21T04:25:39+00:00 weekly 0.7 https://trial.medpath.com/news/5dd76c106f7bed21/rethinking-beta-blocker-use-following-acute-myocardial-infarction 2024-09-21T03:17:28+00:00 weekly 0.7 https://trial.medpath.com/news/d430ff8f6d7ac903/fda-clears-investigational-new-drug-application-for-cd-001-in-oncology 2024-09-21T02:50:46+00:00 weekly 0.7 https://trial.medpath.com/news/263b29a9ffd1ca92/a-precision-medicine-initiative-sponsored-by-the-national-cancer-institute-aims-to-improve 2024-09-21T02:43:57+00:00 weekly 0.7 https://trial.medpath.com/news/dc1f3a4bd3f8128f/ibcn-2024-elucidating-the-response-rates-to-additional-bcg-implications-for-clinical-trial-design 2024-09-21T02:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/869550c185360cd9/cybin-misses-end-of-summer-goal-for-phase-3-study-start-green-market-report 2024-09-21T02:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/12655d2596622e61/on-the-move-dr-michael-lyons-upstate-business-journal 2024-09-21T00:15:42+00:00 weekly 0.7 https://trial.medpath.com/news/f4437fe7cd03ed95/novo-s-phase-ii-miss-in-obesity-oral-amps-up-pressure-on-bd-biocentury 2024-09-21T00:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/a4f967edf7b685ce/actinium-pharmaceuticals-announces-publication-of-results-from-the-phase-3-sierra-trial 2024-09-20T23:59:02+00:00 weekly 0.7 https://trial.medpath.com/news/f1e8d8c0bfc36fcc/revolutionizing-oncology-insights-on-the-fda-s-project-optimus-and-dose-optimization 2024-09-20T23:40:32+00:00 weekly 0.7 https://trial.medpath.com/news/88c9de488d83768e/stereotactic-vs-hypofractionated-radiotherapy-for-inoperable-stage-i-non-small-cell-lung-cancer 2024-09-20T22:48:36+00:00 weekly 0.7 https://trial.medpath.com/news/95ff40f145c3775f/new-cancer-research-breakthrough-has-the-potential-to-save-lives-nbc-boston 2024-09-20T22:38:15+00:00 weekly 0.7 https://trial.medpath.com/news/83db7b70259919d5/director-gagnon-robert-e-sold-365-worth-of-shares-131-units-at-2-79-decreasing-direct 2024-09-20T22:18:46+00:00 weekly 0.7 https://trial.medpath.com/news/5ca618d0b5bb80e2/ibcn-2024-a-randomized-phase-ii-trial-comparing-single-dose-perioperative-instillation 2024-09-20T21:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/e7545ad8d00a2c5e/maeve-lowery-md-on-a-novel-bifunctional-antibody-in-advanced-hepatocellular-carcinoma 2024-09-20T21:47:27+00:00 weekly 0.7 https://trial.medpath.com/news/d58b1f8db2b591af/extended-estrogen-suppression-safe-in-breast-cancer-inside-precision-medicine 2024-09-20T21:30:55+00:00 weekly 0.7 https://trial.medpath.com/news/f96e6ec9bfc2cb0d/clinical-trial-cuts-radiation-time-dramatically-sanford-health-news 2024-09-20T21:25:44+00:00 weekly 0.7 https://trial.medpath.com/news/aadc114302df45a0/rock-you-like-a-migraine-opdp-issues-notice-of-violation-for-misleading-representations 2024-09-20T21:06:16+00:00 weekly 0.7 https://trial.medpath.com/news/5e1f539df482eced/this-week-at-fda-asca-guidances-new-clinical-trial-guidances-and-more-raps 2024-09-20T20:54:08+00:00 weekly 0.7 https://trial.medpath.com/news/bb4b3e9a3007a439/after-july-surge-fda-approvals-for-gi-settle-into-summer-lull-what-you-may-have-missed 2024-09-20T20:42:17+00:00 weekly 0.7 https://trial.medpath.com/news/4e75cc3ad02643bb/acelyrin-straight-move-to-phase-3-ted-studies-makes-it-must-watch-nasdaq-slrn 2024-09-20T20:40:38+00:00 weekly 0.7 https://trial.medpath.com/news/4a1cc58dc624d08e/me-therapeutics-to-begin-testing-of-first-mrna-formulations-from-nanovation-pharmabiz-com 2024-09-20T20:29:20+00:00 weekly 0.7 https://trial.medpath.com/news/96c2881569062bbb/tectonic-therapeutic-reports-findings-from-phase-ia-trial-of-tx45 2024-09-20T20:24:45+00:00 weekly 0.7 https://trial.medpath.com/news/99151ddc41a77672/stanford-car-t-solid-tumor-study-enrolls-first-pediatric-patient 2024-09-20T20:22:30+00:00 weekly 0.7 https://trial.medpath.com/news/7e86d4edde9a08dd/promising-results-from-phase-1-2-trial-of-nkt2152-for-advanced-kidney-cancer 2024-09-20T20:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/d6bc30bfff451d4e/nervgen-pharma-to-present-at-the-unite-2-fight-paralysis-19th-annual-science-advocacy 2024-09-20T20:02:28+00:00 weekly 0.7 https://trial.medpath.com/news/f59e439b6c76e899/fibrobiologics-engages-southern-star-research-as-cro-in-australia-biospace 2024-09-20T20:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/be878cf2f125de17/ipsen-s-iqirvo-r-elafibranor-approved-in-the-european-union-as-first-new-treatment-for 2024-09-20T19:31:21+00:00 weekly 0.7 https://trial.medpath.com/news/89599b2514e92b94/cetylpyridinium-chloride-inhibits-hepatocellular-carcinoma-growth-and-metastasis-through-plos 2024-09-20T17:58:55+00:00 weekly 0.7 https://trial.medpath.com/news/fb6d73819efc900b/eqs-adhoc-brain-biotech-ag-concludes-royalty-monetization-deal-for-up-to-eur-128-88 2024-09-20T17:53:07+00:00 weekly 0.7 https://trial.medpath.com/news/5f77e344141ed02d/fda-approves-nasal-spray-as-first-self-administered-flu-vaccine-healio 2024-09-20T17:22:29+00:00 weekly 0.7 https://trial.medpath.com/news/0193c2768ce630e8/us-fda-approves-zevra-s-genetic-disorder-treatment-yahoo-finance 2024-09-20T17:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/17db527b5c6c5e14/novo-nordisk-and-corbus-pharmaceutical-stocks-plummet-benzinga-benzinga 2024-09-20T17:15:06+00:00 weekly 0.7 https://trial.medpath.com/news/6bf270b70fc33924/ema-announces-positive-opinion-for-sb15-opuviz-samsung-bioepis-and-biogen 2024-09-20T16:57:09+00:00 weekly 0.7 https://trial.medpath.com/news/013f980cbcf3f4a1/astellas-receives-approval-from-the-european-commission-for-vyloytm-zolbetuximab-in 2024-09-20T16:54:56+00:00 weekly 0.7 https://trial.medpath.com/news/aa185398cb4f75c5/intravascular-lithotripsy-a-clinical-trial-snapshot 2024-09-20T16:42:51+00:00 weekly 0.7 https://trial.medpath.com/news/ba68b71939a5c192/fda-alert-pulmonology-drug-approvals-and-recalls-medical-device-updates 2024-09-20T16:41:53+00:00 weekly 0.7 https://trial.medpath.com/news/45a6caaf172b37e8/press-release-tolebrutinib-demonstrated-a-31-delay-in-time-to-onset-of-confirmed-sanofi 2024-09-20T16:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/77840fc94280d76e/ecu-health-pioneers-with-fda-approved-elupro-bioenvelope-in-pacemaker-implantation 2024-09-20T15:48:05+00:00 weekly 0.7 https://trial.medpath.com/news/8bac5e3722f3be01/novo-nordisk-s-1bn-oral-weight-loss-drug-shows-promise-but-raises-questions-in-phase-iia-trial 2024-09-20T15:34:42+00:00 weekly 0.7 https://trial.medpath.com/news/8bbcc086b2f6fb2a/novo-nordisk-s-monlunabant-expectations-dashed-by-phase-ii-data-scrip-citeline 2024-09-20T15:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/dea2ce954e18456d/phase-3-mogwai-trial-to-test-azathioprine-as-first-line-treatment-for-mogad 2024-09-20T15:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/482cb47c5cc1c84c/phase-iii-cabinet-trial-cabozantinib-in-advanced-neuroendocrine-tumors 2024-09-20T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/4ba1aea4986b8385/initial-in-vivo-validation-of-novel-cancer-therapeutics-using-ai-drug-target-review 2024-09-20T15:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/0567c1268d17a164/rx-rundown-maxcyte-roche-and-more-medical-marketing-and-media 2024-09-20T14:44:34+00:00 weekly 0.7 https://trial.medpath.com/news/c1ff7cbaebe3c6c6/henlius-biotech-s-drug-nears-eu-approval-tipranks-com 2024-09-20T14:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/ee364b692dcdbc1b/inavolisib-shows-promising-disease-control-rates-safety-in-patients-with-pik3ca-mutated 2024-09-20T14:36:36+00:00 weekly 0.7 https://trial.medpath.com/news/f5a2678fad9d1867/new-listings-in-avma-veterinary-clinical-trials-registry-september-2024 2024-09-20T14:34:17+00:00 weekly 0.7 https://trial.medpath.com/news/aa7e67b854f641da/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-16-19 2024-09-20T14:33:39+00:00 weekly 0.7 https://trial.medpath.com/news/fb92a311087f00d1/apellis-eye-drug-again-turned-back-in-europe-biopharma-dive 2024-09-20T14:28:26+00:00 weekly 0.7 https://trial.medpath.com/news/e63dd04d40de997c/an-optimized-strategy-triggered-at-the-2nd-immunization-visit-to-prevent-hiv-acquisition-by 2024-09-20T14:28:21+00:00 weekly 0.7 https://trial.medpath.com/news/6b24130b1b6a7dcb/aligos-reports-positive-data-from-phase-iia-mash-treatment-trial 2024-09-20T14:25:18+00:00 weekly 0.7 https://trial.medpath.com/news/a61382f992d9756b/targeted-therapies-novel-antibodies-and-immunotherapies-in-advanced-non-small-cell 2024-09-20T14:19:52+00:00 weekly 0.7 https://trial.medpath.com/news/dbf014574c9f511d/breakthrough-as-common-drug-shrinks-fatal-and-aggressive-brain-tumours-raising-hopes-of-a-cure 2024-09-20T14:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/9eadcedf7f456eac/novo-s-next-gen-cb1-drug-leads-to-weight-loss-in-phase-ii-but-neuropsychiatric-events-reported 2024-09-20T14:11:36+00:00 weekly 0.7 https://trial.medpath.com/news/b6f88b2d935c5919/atezolizumab-venetoclax-and-obinutuzumab-in-richter-transformation-diffuse-large-b 2024-09-20T14:02:46+00:00 weekly 0.7 https://trial.medpath.com/news/c3efdbbaae05e645/revolution-or-mirage-controversy-surrounds-new-alzheimer-s-drugs-medical-xpress 2024-09-20T13:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/351ecaaef6143b61/darzalex-r-daratumumab-based-quadruplet-regimen-receives-positive-chmp-opinion-for 2024-09-20T13:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/62f1e0f61427f2c8/novel-btk-inhibitor-lp-168-under-investigation-in-china-for-r-r-mantle-cell-lymphoma 2024-09-20T13:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/755085fe52fd725f/alpha-tau-announces-fda-approval-of-ide-to-initiate-multi-center-investigator-morningstar 2024-09-20T12:56:13+00:00 weekly 0.7 https://trial.medpath.com/news/cf85054b589aff95/where-will-amgen-be-in-5-years-aol-com 2024-09-20T12:49:11+00:00 weekly 0.7 https://trial.medpath.com/news/bf74a0bacac86696/biosyngen-best-in-class-next-generation-tumor-infiltrating-lymphocyte-til-technology 2024-09-20T12:32:26+00:00 weekly 0.7 https://trial.medpath.com/news/90c6daaf877d0d16/press-release-dupixent-recommended-for-eu-approval-by-the-chmp-to-treat-eosinophilic-sanofi 2024-09-20T12:06:28+00:00 weekly 0.7 https://trial.medpath.com/news/327a8ba1748f9685/kangpu-completed-bridging-clinical-study-of-kpg-818-in-china-pr-newswire 2024-09-20T12:02:23+00:00 weekly 0.7 https://trial.medpath.com/news/dbb33f628f787bf8/marinus-pharmaceuticals-to-highlight-clinical-progress-and-commercial-launch-stock-titan 2024-09-20T12:01:20+00:00 weekly 0.7 https://trial.medpath.com/news/c6a8dd8aa1d6d8ca/merck-receives-positive-eu-chmp-opinions-for-keytruda-r-pembrolizumab-regimens 2024-09-20T11:36:14+00:00 weekly 0.7 https://trial.medpath.com/news/9deef25031563236/abbvie-receives-positive-chmp-opinion-for-mirvetuximab-soravtansine-elahere-r-for 2024-09-20T11:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/8446fb5528396719/apellis-receives-negative-chmp-opinion-for-pegcetacoplan-for-geographic-atrophy-ga-in 2024-09-20T11:26:55+00:00 weekly 0.7